---
title: "Varegacestat (AL102) in Desmoid tumors: Clinical evidence"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Clinical evidence. Covers RINGSIDE part B, RINGSIDE part A, CA002-001, AL102-501, AL102-502, AL102-503, and 2 further headings. 319 evidence topics quoted from 39 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 RINGSIDE Part B

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Part B primary objective: effect on disease progression

> “Part B (Phase III): To evaluate effects of AL102 on disease progression in subjects with progressing desmoid tumors”

Source: [EU Clinical Trials Information System 2024-515909-26-00](https://euclinicaltrials.eu/ctis-public/view/2024-515909-26-00)

<a id="topic-3.1.1.1-2"></a>

###### Part B secondary objectives: tumor response, quality of life, and safety

> “Part B: To evaluate additional effects of AL102 on tumor response”
> “Part B: To evaluate effects of AL102 on quality of life;”
> “Part B: To evaluate the safety and tolerability of AL102 in subjects with progressing desmoid tumors”
> “OLE: To evaluate the efficacy of AL102 in subjects with progressive desmoid tumors”

Source: [EU Clinical Trials Information System 2024-515909-26-00 API record](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515909-26-00)

<a id="topic-3.1.1.1-3"></a>

###### Efficacy, safety, and tolerability compared with placebo

> “It is designed to evaluate the efficacy, safety and tolerability of varegacestat compared to placebo in participants with progressing desmoid tumors.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-3.1.1.1-4"></a>

###### Registry summary of the study purpose

> “The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Enrollment period and data cutoff

> “Enrollment: Nov. 15, 2022 ‒ Feb 14, 2024”
> “Data-cutoff date: October 7, 2025”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.2-2"></a>

###### Data cutoff of the primary analysis abstract

> “As of Oct 7, 2025, median duration of exposure was 20.3 months (range 0.8 – 34.6) for VAR and 11.1 months (range 0.2 – 34.6) for PBO.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-3.1.1.2-3"></a>

###### Global conduct and completion of enrollment

> “The Phase 3 portion of RINGSIDE is a registrational, global, double-blind, randomized, placebo-controlled clinical trial, conducted at clinical sites in North America, Europe, Asia and Australia.”
> “Enrollment was completed in February 2024.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-3.1.1.2-4"></a>

###### Registry status and dates for the combined Part A, Part B, and open-label extension record

| Study characteristic | Quoted record |
| --- | --- |
| Overall status | “Active, not recruiting” |
| Study start (actual) | “2021-09-01” |
| Primary completion (actual) | “2025-12-03” |
| Study completion (estimated) | “2026-12” |
| Number of locations | “This study has 53 locations” |

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.1.2-5"></a>

###### Registry sites by country

| Country | Quoted site names |
| --- | --- |
| United States | “Memorial Sloan Kettering Cancer Center”; “MD Anderson Cancer Center”; “Stanford University Medical Center”; “University of Michigan” |
| Australia | “Peter MacCallum Cancer Centre”; “Adelaide Cancer Centre” |
| Belgium | “Universitaire Ziekenhuizen Leuven” |
| Germany | “Mannheim university medical center” |
| Israel | “Rambam MC”; “Tel Aviv Sourasky Medical Center” |
| Italy | “IRCCS Fondazione Istituto Nazionale dei Tumori” |
| Netherlands | “The Netherlands Cancer Institute” |
| Poland | “Maria Sklodowska-Curie National Research Institute of Oncology” |
| South Korea | “Severance Hospital, Yonsei University Health System” |
| Spain | “Hospital Universitario Fundacion Jimenez Diaz” |
| United Kingdom | “The Royal Marsden Hospital” |

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.1.2-6"></a>

###### European Union member states, start of trial, and end of recruitment

> “Spain, Germany, Italy, Poland, Netherlands, Belgium”
> “Start of trial 26/01/2022”
> “Netherlands Ongoing, recruitment ended 30/10/2024 11/08/2026 26/01/2022 09/02/2022 14/02/2024”
> “Estimated global end date of the trial:”
> “15/12/2026”

Source: [EU Clinical Trials Information System 2024-515909-26-00](https://euclinicaltrials.eu/ctis-public/view/2024-515909-26-00)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Double-blind, placebo-controlled, randomized phase 3 design with central imaging review

> “RINGSIDE Phase 3 was a double-blind, placebo (PBO)-controlled study in adults with progressing DT per RECIST v1.1 (NCT04871282).”
> “156 pts were randomized 1:1 to once daily oral VAR 1.2 mg (n=79) or PBO (n=77).”
> “Imaging-based tumor response was assessed per RECIST v1.1 by blinded independent central review.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-3.1.1.3-2"></a>

###### Registry design record

| Study characteristic | Quoted record |
| --- | --- |
| Official title | “RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors” |
| Study type | “Interventional” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Protocol number | “AL-DES-01” |
| EU trial number | “2024-515909-26-00” |

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.1.3-3"></a>

###### Stratification by tumor location

> “Randomized 1:1”
> “Stratification factors:”
> “Tumor location (intra- vs. extra-abdominal)”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.3-4"></a>

###### Crossover to the open-label extension

> “crossover to OLE from either arm allowed if progressive disease.”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “Cross over to OLE”
> “if progressive disease”
> “if active at primary analysis”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

> “Participants who progress while on study are eligible to enter an open-label extension whereby they may receive varegacestat at a dose of 1.2 mg once daily until disease progression or unacceptable toxicity.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-3.1.1.3-5"></a>

###### Open-label extension ongoing

> “RINGSIDE includes an open-label extension phase, which is ongoing.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="topic-3.1.1.3-6"></a>

###### Relationship between Part A dose finding and Part B

> “This is a Phase 2/3, randomized study in subjects with progressive desmoid tumors consisting of 2 parts. Phase2/Part A is an open-label, dose regimen finding study; Phase3/Part B is a double blind, placebo-controlled study and Open Label Extension utilizing the dose regimen selected in Phase2/Part A.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

> “Based on these data and responses demonstrated with other GSIs, Ayala designed a seamless Phase 2/3 study called RINGSIDE to specifically evaluate the activity of varegacestat in participants with progressing desmoid tumors who required therapy.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “The RINGSIDE Phase 2 dose-finding study identified the GSI varegacestat 1.2 mg once daily as the dose for Phase 3 study”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “The largest responses were seen with the 1.2-mg once-daily dose, which was selected for the RINGSIDE phase III trial.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.1.3-7"></a>

###### Sponsorship and funding

> “The RINGSIDE study (NCT04871282) was sponsored/funded by Immunome and Ayala Pharmaceuticals, Inc.”

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Key eligibility criteria as presented for the primary analysis

> “Adults with histologically confirmed DT that has progressed in the past 12 months per RECIST 1.1”
> “Treatment-naïve and previously treated patients”
> “Measurable disease”
> “ECOG PS score 0-1”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.4-2"></a>

###### Part B inclusion criteria in the registry record

> “≥12 years of age (inclusive) and ≥ 40 kg at the time of signing the ICF.”
> “Histologically confirmed desmoid tumor (aggressive fibromatosis) by local pathologist (prior to informed consent) that has progressed by ≥ 20% as measured by RECIST v1.1 within 12 months of the screening visit scan.”
> “Evidence of measurable disease by CT/MRI scan. Measurable lesions are defined according to RECIST v1.1.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.1.4-3"></a>

###### Additional Part B inclusion criteria in the EU trial record

> “Part B: 1. ≥12 years of age (inclusive) in countries which allow participation of adolescents and ≥ 40 kg at the time of signing the ICF.”
> “Part B: Histologically confirmed desmoid tumor (aggressive fibromatosis) by local pathologist (prior to informed consent) that has progressed per RECIST v1.1 (≥20% or new lesion) by investigator within 12 months of the screening visit scan.”
> “Part B: One of the following: • Recurrent/refractory disease following at least one line of therapy (including surgery, radiation, or systemic therapy); OR • Treatment naïve subjects for whom, in the opinion of the investigator, surgery or radiation therapy is not deemed appropriate;”
> “Part B: A desmoid tumor in which continued progressing disease will not result in immediate significant risk to the subject.”
> “Part B: Must be able to swallow whole capsules with no GI condition affecting absorption (not including history of colectomy or proctocolectomy); nasogastric or G-tube administration is not allowed”

Source: [EU Clinical Trials Information System 2024-515909-26-00 API record](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515909-26-00)

<a id="topic-3.1.1.4-4"></a>

###### Prior treatment status of enrolled participants

> “Enrolled participants were either treatment-naïve with desmoid tumors not amenable to surgery or had refractory or recurrent disease after at least one line of therapy.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-3.1.1.4-5"></a>

###### Exclusion criteria for Parts A and B in the registry record

> “Diagnosed with a malignancy in the past 2 years with some exceptions.”
> “Current or recent (within 2 months of IP administration) GI disease or disorders that increase the risk of diarrhea, such as inflammatory bowel disease and Crohn's disease.”
> “Pregnant or breastfeeding or expecting to conceive children within the projected duration of the study.”
> “Eastern Cooperative Oncology Group (ECOG) performance status ≥2”
> “Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥450 msec.”
> “Any treatments for desmoid tumors within 4 weeks prior to first dose of investigational therapy; subject must have recovered from therapy related toxicity to < CTCAE Grade 2 or clinical baseline.”
> “Systemic therapy including chemotherapy, biologic (anti-neoplastic agent, antibodies), TKIs (e.g., sorafenib, pazopanib, imatinib), hormonal therapy, or investigational therapy”
> “Chronic NSAIDs for the treatment of desmoid tumors within 4 weeks of first dose of IP”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.1.4-6"></a>

###### Additional Part B exclusion criteria in the EU trial record

> “Part B: History of additional risk factors for TdP”
> “Part B: ECG Exclusions: a. Mean QTcF ≥450 msec; b. Second or third degree AV block”

Source: [EU Clinical Trials Information System 2024-515909-26-00 API record](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515909-26-00)

<a id="topic-3.1.1.4-7"></a>

###### Open-label extension entry criteria

> “Participated in Part A (including MRI at Week 16) and were still on study at time that Part B/OLE dose selection was made, OR”
> “Participating in Part B and were noted to have radiographic progressive disease by BICR, OR”
> “Are on study treatment (placebo or varegacestat) after completion of Part B”
> “Any participant with an ongoing TEAE (including abnormal laboratory results) from Part A or Part B that requires discontinuation from the study, will not be eligible to enter the open-label extension.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Randomized treatment arms

> “156 pts were randomized 1:1 to once daily oral VAR 1.2 mg (n=79) or PBO (n=77).”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

| Arm | Quoted registry description |
| --- | --- |
| Part B AL102 | “AL102, recommended dose regimen from Part A, 1.2 mg daily” |
| Part B placebo | “Placebo to match recommended dose regimen from Part A” |
| Open-label extension | “AL102, recommended dose regimen from Part A, 1.2 mg daily” |
| Study drug | “AL102 is an inhibitor of gamma secretase-mediated Notch signaling.” |

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.1.5-2"></a>

###### Treatment duration

> “A total of 156 patients were randomized to receive varegacestat 1.2 mg daily or placebo until disease progression or death”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="topic-3.1.1.5-3"></a>

###### Dose levels used for dose reduction

> “Median Time to First Dose Reduction”
> “to 0.9 mg (n=60): 3.7 (IQR 1.8, 8.3) months”
> “to 0.6 mg (n=36): 7.3 (IQR 3.0, 12.5) months”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.5-4"></a>

###### Capsule formulation

> “Part B: Must be able to swallow whole capsules with no GI condition affecting absorption (not including history of colectomy or proctocolectomy); nasogastric or G-tube administration is not allowed”

Source: [EU Clinical Trials Information System 2024-515909-26-00 API record](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515909-26-00)

<a id="topic-3.1.1.5-5"></a>

###### Prohibited prior desmoid tumor therapy before the first dose

> “Locoregional tumor directed therapies such as major surgery, radiation, radiofrequency ablation, or cryosurgery”
> “Chronic NSAIDs for the treatment of desmoid tumors within 4 weeks of first dose of IP”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Progression-free Survival as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary endpoint: progression-free survival by blinded independent central review per RECIST v1.1

> “PFS as defined as the time from randomization until the date of assessment of progression as assessed by BICR based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death by any cause”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

> “PFS was defined as time from randomization until the date of assessment of radiographic progression as assessed Blinded Independent Central Review (BICR) based on RECIST v1.1”
> “Progression was defined as ≥20% increase per RECIST v1.1”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

<a id="topic-3.1.1.6.1-2"></a>

###### Primary endpoint in the EU trial record

> “Part B: Progression free survival”

Source: [EU Clinical Trials Information System 2024-515909-26-00 API record](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515909-26-00)

<a id="topic-3.1.1.6.1-3"></a>

###### Design consistent with prior registrational trials

> “Design consistent with prior registrational trials”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

<a id="topic-3.1.1.6.1-4"></a>

###### Precedent: progression-free survival as the primary end point of DeFi

> “The DeFi (Desmoid Fibromatosis) trial was a phase 3, international, double-blind, randomized, placebo-controlled trial to determine the efficacy and safety of nirogacestat in patients 18 years of age or older with a histologically confirmed diagnosis of progressing desmoid tumors (defined as ≥20% progression according to the Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1, within 12 months before screening).”
> “The primary end point was progression-free survival, defined as the time from randomization until the date of imaging-based or clinical progression or death.”
> “Both imaging-based and clinical progression were confirmed by blinded independent central review.”

Source: [Gounder et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225596/)

<a id="topic-3.1.1.6.1-5"></a>

###### Precedent: progression-free survival as the major efficacy outcome in the nirogacestat label

> “The major efficacy outcome was progression-free survival (PFS) based on RECIST v1.1 as assessed by blinded independent central review or on clinical progression by the investigator (and confirmed by independent review).”
> “Crossover was permitted at the time of radiographic progression.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-3.1.1.6.1-6"></a>

###### Precedent: progression-free survival as the primary end point of the sorafenib phase 3 trial

> “The primary end point was progression-free survival, as determined by the treating physicians in accordance with RECIST, version 1.1.”

Source: [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/)

<a id="topic-3.1.1.6.1-7"></a>

###### Variable natural history and the need for a placebo control

> “Interpretation of the data is challenging, given the unpredictable natural history of the condition. Desmoid tumors can show rapid growth followed by periods of stabilization, spontaneous regression, or subsequent growth phases.”

Source: [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/)

> “In a phase 3 trial of sorafenib involving adults with desmoid tumors, progression-free survival was significantly longer with sorafenib than with placebo (P<0.001); however, 20% of the participants in the placebo group had an objective response, a finding that highlights the need for a placebo control in this population.”

Source: [Gounder et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225596/)

> “The ORR was 33% for sorafenib; however, the placebo arm ORR was as high as 20% demonstrating spontaneous regression and giving useful information on the natural history of this disease.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

> “Spontaneous regressions are observed in as many as 20%–30% of cases”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-3.1.1.6.1-8"></a>

###### Limitations of RECIST and progression-free survival in desmoid tumors

> “RECIST does not robustly identify all clinically relevant responses, though the majority of prospective trials report efficacy using RECIST.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

> “The dimension-based RECIST is currently employed within clinical trials”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

> “Existing clinical trial endpoints such as the Response Evaluation Criteria in Solid Tumors (version 1.1) and progression-free survival are inadequate in capturing treatment efficacy.”
> “These surrogate endpoints for overall survival may not be appropriate for a disease with low mortality and importantly fail to capture whether treatments truly improve symptoms and/or affect daily living.”

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

<a id="topic-3.1.1.6.1-9"></a>

###### Alpha-controlled key secondary endpoints

> “The primary endpoint was progression-free survival (PFS).”
> “Alpha-controlled secondary endpoints were confirmed objective response rate (ORR), change in tumor volume (TV) at Week 24, and change in patient-reported worst pain intensity (WPI) at Week 12.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “Statistically controlled secondary endpoints were confirmed ORR using RECIST v1.1 and change in tumor volume at week 24, both determined by blinded independent central review, as well as change in pain intensity at week 12 as determined using a patient-reported outcome instrument.”
> “Additional secondary endpoints included duration of response, best reduction in tumor volume, patient-reported outcomes, and safety and tolerability.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="topic-3.1.1.6.1-10"></a>

###### Key secondary endpoint: objective response rate by blinded independent central review per RECIST v1.1

> “Defined as the proportion of subjects with confirmed ORR (complete response [CR] and partial response [PR]) by BICR based on RECIST v1.1.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.1.6.1-11"></a>

###### Key secondary endpoint: tumor volume at Week 24 by T2-weighted MRI or CT

> “Change from baseline at Week 24 in estimated tumor volume measured by T2 weighted (T2W) MRI or CT by BICR”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

> “Measured by T2 weighted MRI or CT per BICR”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

<a id="topic-3.1.1.6.1-12"></a>

###### Rationale for volumetric and T2-weighted MRI assessment

> “T2-weighted (T2W) signal intensity and tumor volume on MRI may be more sensitive than RECIST for assessing treatment effect in desmoid tumors (DTs)”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

> “The retrospective study also highlighted that RECIST may underestimate efficacy and that a better criterion may be magnetic resonance imaging (MRI) T2-weighted signal intensity, an imaging biomarker that signifies a biologic transformation from a cellular tumor to a collagenous scar.”
> “Exploratory imaging end points included a comparison of RECIST measurements with total tumor volume and MRI T2-weighted signal intensity in patients.”

Source: [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/)

> “MRI surveillance has been used to assess response to treatment with a decrease in T2W signal and lesion size”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-3.1.1.6.1-13"></a>

###### Tumor assessments by blinded independent central review in the primary analysis poster

> “Tumor Assessments by BICR”
> “Response per RECIST v1.1”
> “Tumor volume (TV)”
> “T2W signal intensity”
> “Findings add to a growing body of work showing T2W may play a role in evaluating treatment response in DT.”

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

<a id="topic-3.1.1.6.1-14"></a>

###### Key secondary endpoint: GODDESS worst pain intensity at Week 12

> “Change from baseline to Week 12 in the worst pain intensity (WPI) using GOunder/Desmoid Tumor Research Foundation (DTRF) DEsmoid Symptom Scale and Impact Scale (GODDESS) Desmoid Tumor Symptom Scale (DTSS)”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

> “Measured using Desmoid Tumor Symptom Scale Item 1 from the GOunder/Desmoid Tumor Research Foundation Desmoid Tumor Symptom/Impact Scale (GODDESS)”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

<a id="topic-3.1.1.6.1-15"></a>

###### GODDESS scoring and administration in RINGSIDE

> “Higher Scores = Worse Symptoms; scored on 0 to 10 scale”
> “Domains and Items scored 0 (no symptoms) to 10 (worse symptoms imaginable)”
> “Completed as a daily diary for 7 days (scores averaged over the 7 days), at baseline and every 4 weeks”
> “Clinically meaningful thresholds were derived from the RINGSIDE population”

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

<a id="topic-3.1.1.6.1-16"></a>

###### Rationale for GODDESS as a disease-specific endpoint

> “This study was designed to develop a novel clinical trial endpoint by capturing patient-reported outcomes (PROs).”
> “This is the first disease-specific PRO instrument developed for desmoid tumors.”

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

> “GODDESS© was found to be reliable, valid, responsive, and interpretable as a clinical trial endpoint in the pooled sample of DT/AF patients.”

Source: [Gounder et al. (2023c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10474203/)

<a id="topic-3.1.1.6.1-17"></a>

###### Exploratory patient-reported endpoints: GODDESS symptom scores and PROMIS Physical Function

> “Select PRO Exploratory Endpoints:”
> “Change from baseline in pain and DT symptoms (GODDESS)”
> “Change from baseline in Physical Functioning (PROMIS Physical Functioning 10a)”
> “(Pain intensity, fatigue, swelling, muscle weakness, difficulty moving)”
> “Higher Scores = Better Function”
> “Items scored on a scale of 1 (cannot do) to 5 (can do without any difficulty/ not impacted)”
> “Completed once at baseline and every 4 weeks”

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

<a id="topic-3.1.1.6.1-18"></a>

###### Other Part B secondary endpoints in the registry record

| Endpoint | Quoted registry definition |
| --- | --- |
| Duration of response | “Defined by the time from confirmed CR or PR (by BICR based on RECIST v1.1) until the earlier of the first documentation of disease progression or death from any cause” |
| Progression-free survival including clinical progression | “Defined as the time from randomization until the date of radiographic progression as assessed by BICR or clinical progression as assessed by the investigator or death by any cause” |
| Adverse events | “Evaluation of the safety and tolerability of AL102 in subjects with progressing desmoid tumors as defined by the frequency and severity of TEAEs and SAEs” |
| Time to treatment discontinuation | “Evaluation of the safety and tolerability of AL102 in subjects with progressing desmoid tumors as defined by the time to treatment discontinuation due to TEAE” |

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.1.6.1-19"></a>

###### Part B secondary end points in the EU trial record

> “Part B: proportion of subjects with confirmed ORR”
> “Part B: duration of response”
> “Part B: PFS as defined as the time from randomization until the date of radiographic progression by BICR or clinical progression”
> “Part B: Change from baseline at Week 24 in estimated tumor volume”
> “Part B: Change from baseline to Week 12 in the worst pain intensity (WPI)”
> “Part B: frequency and severity of TEAEs and SAEs”
> “Part B: time to treatment discontinuation due to TEAE”

Source: [EU Clinical Trials Information System 2024-515909-26-00 API record](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515909-26-00)

<a id="topic-3.1.1.6.1-20"></a>

###### Registry secondary outcome measures without Week 24 and Week 12 time points, February 2026, superseded in June 2026

> “Viewing V37 (2026-02-03)”
> “Change from baseline in estimated tumor volume measured by T2 weighted (T2W) MRI or CT by BICR (based on RECIST v1.1)”
> “Change from baseline in pain assessment using GOunder/Desmoid Tumor Research Foundation (DTRF) DEsmoid Symptom Scale and Impact Scale (GODDESS) Desmoid Tumor Symptom Scale (DTSS)”

Source: [ClinicalTrials.gov NCT04871282 version 37](https://clinicaltrials.gov/study/NCT04871282?tab=history&a=37)

<a id="topic-3.1.1.6.1-21"></a>

###### Registry secondary outcome measures with PROMIS, EQ-5D, and Brief Pain Inventory, November 2024, superseded in May 2025

> “Viewing V35 (2024-11-06)”
> “36 2025-05-31 Study Status Oversight Study Design Arms and Interventions Outcome Measures Contacts/Locations”
> “Change from baseline in quality of life as measured by GOunder/Desmoid Tumor Research Foundation (DTRF) DEsmoid Symptom Scale and Impact Scale (GODDESS)”
> “Change from baseline in quality of life as measured by Patient-reported outcomes measurement information system (PROMIS) Physical Function”
> “Change from baseline in quality of life as measured by EuroQol 5-dimensional questionnaire(EQ-5D)”
> “Change from baseline in pain assessment using brief pain inventory (BPI) short form”

Source: [ClinicalTrials.gov NCT04871282 version 35](https://clinicaltrials.gov/study/NCT04871282?tab=history&a=35)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Participants randomized in Part B

> “156 pts were randomized 1:1 to once daily oral VAR 1.2 mg (n=79) or PBO (n=77).”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “One hundred fifty-six participants with histologically confirmed desmoid tumors with progressive disease (defined as tumor growth of at least 20% within the past 12 months as measured by RECIST v1.1) were enrolled.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-3.1.1.7.1-2"></a>

###### Participants analyzed for progression-free survival

> “No. of Patients”
> “No. of Events”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

| Arm | Participants analyzed | Events |
| --- | --- | --- |
| Varegacestat | “79” | “7” |
| Placebo | “77” | “29” |

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.7.1-3"></a>

###### Registry enrollment for the combined record

> “Enrollment (Actual)”
> “198”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.1.7.1-4"></a>

###### Part A enrollment within the combined registry record

> “In total, 42 participants enrolled in the randomized trial (14 per dose arm).”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.1.7.1-5"></a>

###### Planned enrollment in the registry record, November 2024, superseded in May 2025

> “Viewing V35 (2024-11-06)”
> “192 [Estimated]”

Source: [ClinicalTrials.gov NCT04871282 version 35](https://clinicaltrials.gov/study/NCT04871282?tab=history&a=35)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Intention-to-treat population defined as all participants who received at least one dose

> “Population: all participants who received ≥1 dose of study drug (i.e., the intention-to-treat population).”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.7.2-2"></a>

###### Hazard ratio model stratified by tumor location

> “Hazard ratio estimated from Cox proportional hazards model stratified by tumor location (intra-abdominal vs extra-abdominal)”
> “Post-hoc subgroup analysis to evaluate patients with poor prognosis”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.7.2-3"></a>

###### Hierarchy of alpha-controlled and non-alpha-controlled endpoints

> “Alpha-controlled secondary endpoints were confirmed objective response rate (ORR), change in tumor volume (TV) at Week 24, and change in patient-reported worst pain intensity (WPI) at Week 12.”
> “Not alpha-controlled endpoint.”
> “LS, least square; SE, standard error.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-3.1.1.7.2-4"></a>

###### Patient-reported outcome analyses in the intention-to-treat population with mixed models for repeated measures

> “Analyses on ITT population; symptoms at baseline were not an enrollment criterion”
> “Least-square (LS) means derived from mixed model for repeated measures (MMRM)”

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

<a id="topic-3.1.1.7.2-5"></a>

###### Descriptive analysis of RECIST diameters, tumor volume, and T2-weighted signal

> “Descriptive Analysis”
> “Change from baseline in RECIST sum of diameters (SOD), TV, and T2W signal intensity”

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

<a id="topic-3.1.1.7.2-6"></a>

###### Kaplan-Meier estimation of duration of response

> “Duration of response (months), median (95% CI)”
> “Kaplan-Meier estimate. DOR, duration of response; RECIST, Response Evaluation Criteria in Solid Tumors, version 1.1”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Randomized participants by arm

> “156 pts were randomized 1:1 to once daily oral VAR 1.2 mg (n=79) or PBO (n=77).”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-3.1.1.8.1-2"></a>

###### Enrollment period and data cutoff

> “Enrollment: Nov. 15, 2022 ‒ Feb 14, 2024”
> “Data-cutoff date: October 7, 2025”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.8.1-3"></a>

###### Duration of exposure by arm

> “As of Oct 7, 2025, median duration of exposure was 20.3 months (range 0.8 – 34.6) for VAR and 11.1 months (range 0.2 – 34.6) for PBO.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “Varegacestat 20 months | Placebo 11 months”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “The median exposure was 20.3 months for patients receiving varegacestat vs. 11.1 months for placebo.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="topic-3.1.1.8.1-4"></a>

###### Discontinuation due to adverse events by arm

> “16 (20%) VAR pts and 5 (7%) PBO pts discontinued due to AEs.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “Discontinuation Due to AEs: Varegacestat 20% | Placebo 6%”

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

<a id="topic-3.1.1.8.1-5"></a>

###### Treatment duration and absence of progressive disease with varegacestat

> “Median treatment duration: 20 months”
> “Note: No varegacestat participants had progressive disease (PD).”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.8.1-6"></a>

###### Open-label extension ongoing

> “RINGSIDE includes an open-label extension phase, which is ongoing.”

Source: [Immunome press release, ESMO 2026 data (2026)](https://investors.immunome.com/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026/)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Balance between arms

> “Demographics and disease characteristics were balanced between treatment arms.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-3.1.1.8.2-2"></a>

###### Demographics, tumor characteristics, and prior therapy

| Characteristic, n (%) | Varegacestat (n=79) | Placebo (n=77) |
| --- | --- | --- |
| Median age (range), years | “42.0 (18–66)” | “39.0 (20–69)” |
| Male | “26 (32.9)” | “29 (37.7)” |
| Female | “53 (67.1)” | “48 (62.3)” |
| Premenopausal | “36 (45.6)” | “38 (49.4)” |
| Target tumor location: extra-abdominal | “60 (75.9)” | “49 (63.6)” |
| Target tumor location: intra-abdominal | “19 (24.1)” | “28 (36.4)” |
| Medical history of FAP | “7 (8.9)” | “8 (10.4)” |
| Median target tumor size per RECIST (range), mm | “75.1 (18.0, 244.9)” | “84.8 (21.3, 666.3)” |
| Any prior therapy | “52 (65.8)” | “60 (77.9)” |
| Prior surgery | “24 (30.4)” | “33 (42.9)” |
| Prior radiation therapy | “8 (10.1)” | “12 (15.6)” |
| Prior systemic therapy | “43 (54.4)” | “46 (59.7)” |
| Prior systemic therapies: 0 lines | “36 (45.6)” | “31 (40.3)” |
| Prior systemic therapies: 1 line | “25 (31.6)” | “22 (28.6)” |
| Prior systemic therapies: 2 or more lines | “18 (22.8)” | “24 (31.2)” |

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.8.2-3"></a>

###### Definition of prior systemic therapy and rounding

> “Includes chemotherapy, tyrosine kinase inhibitors, and hormonal therapy”
> “Percentages may not total 100 because of rounding.”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.8.2-4"></a>

###### Premenopausal women as a proportion of female participants

| Characteristic | Varegacestat (n=79) | Placebo (n=77) |
| --- | --- | --- |
| Premenopausal, n/N of female participants (%) | “36/53 (67.9)” | “38/48 (79.2)” |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.8.2-5"></a>

###### Baseline worst pain intensity

> “At baseline, the mean WPI score was 4.43 for varegacestat and 4.94 for placebo.”
> “Approximately 80% had a score of ≥2.”

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

<a id="topic-3.1.1.8.2-6"></a>

###### Baseline symptom burden and physical function

> “Average baseline score across arms was approximately 4 indicating moderate symptom burden.”
> “A T-score of 50 reflects the average level of physical functioning in a general population; average baseline score across arms was approximately 45, indicating mild functional impairment.”

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Primary endpoint: progression-free survival

> “VAR demonstrated significantly better PFS compared with PBO (hazard ratio [HR]: 0.16 [95% CI: 0.07, 0.38; P<0.0001]).”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-3.1.1.8.3-2"></a>

###### RINGSIDE phase 3 trial outcomes table

| Outcome | VAR (n=79) | PBO (n=77) | HR (95% CI) or Difference; P value |
| --- | --- | --- | --- |
| Median PFS (95% CI), radiographic, months | “NE (NE, NE)” | “24.9 (13.8, NE)” | “0.16 (0.07, 0.38); P<0.0001” |
| Confirmed ORR, n (%) | “44 (55.7)” | “7 (9.1)” | “P<0.0001” |
| TV change (cm3) at Week 24, LS mean (SE) | “-109.6 (40.64)” | “122.8 (42.72)” | “-232.4 (57.39); P<0.0001” |
| WPI (pain) change at Week 12, LS mean (SE) | “-2.24 (0.27)” | “0.18 (0.27)” | “-2.42 (0.37); P<0.0001” |
| Median best % change in TV (not alpha-controlled) | “-83.4” | “11.3” | |

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-3.1.1.8.3-3"></a>

###### Progression-free survival events and median, ASCO 2026 presentation

| Arm | No. of patients | No. of events | Median PFS (95% CI) (mo) |
| --- | --- | --- | --- |
| Varegacestat | “79” | “7” | “NE (NE, NE)” |
| Placebo | “77” | “29” | “24.87 (13.80, NE)” |

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “0.16 (95% CI, 0.07, 0.38) P<0.0001”
> “84% reduction in the risk of radiographic disease progression or death with varegacestat vs. placebo”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.8.3-4"></a>

###### Progression-free survival hazard ratio with confidence limits to three decimal places

> “The trial met its primary endpoint of improving progression-free survival, demonstrating a statistically significant and clinically meaningful improvement vs. placebo, with an 84% reduction in the risk of disease progression or death (hazard ratio (HR) = 0.16, 95% CI: 0.071, 0.375; p<0.0001).”

Source: [Immunome press release, RINGSIDE topline results (2025)](https://investors.immunome.com/immunome-announces-positive-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors/)

> “Progression-Free Survival: HR 0.16; 95% CI: 0.071, 0.375; p < 0.0001”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

> “Progression-Free Survival: HR 0.16; 95% CI: 0.071, 0.375; p < 0.0001”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-3.1.1.8.3-5"></a>

###### Landmark progression-free survival rates at 1 and 2 years

| Arm | 1 Year | 2 Years |
| --- | --- | --- |
| Varegacestat | “94% (95% CI: 85–98%)” | “89% (95% CI: 78–95%)” |
| Placebo | “66% (95% CI: 52–76%)” | “57% (95% CI: 43–69%)” |

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

<a id="topic-3.1.1.8.3-6"></a>

###### Progression-free survival subgroups

> “PFS consistently favored VAR in all subgroups analyzed.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “Post-hoc subgroup analysis to evaluate patients with poor prognosis”
> “Hazard ratio estimated from Cox proportional hazards model stratified by tumor location (intra-abdominal vs extra-abdominal)”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “PFS consistently favored varegacestat in all subgroups analyzed”
> “Male/female”
> “Age ≤30 / >30 years”
> “Baseline tumor size >10 / ≤10 cm”
> “Prior systemic DT therapy (yes/no)”

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

> “The PFS benefit observed with varegacestat vs. placebo was consistent across key subgroups, including tumor location, baseline tumor size, patient age and prior systemic desmoid tumor therapy.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="topic-3.1.1.8.3-7"></a>

###### Key secondary endpoint: confirmed objective response rate and complete responses

> “ORR was significantly better with VAR vs PBO (55.7% vs 9.1%; P<0.0001), with 3 CRs in the VAR arm and 1 CR in the PBO arm.”
> “Median duration of response was not reached in either arm.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-3.1.1.8.3-8"></a>

###### Objective response, time to response, and best overall response

| Outcome | Varegacestat (n=79) | Placebo (n=77) |
| --- | --- | --- |
| Objective response rate, n (%) [95% CI] | “44 (55.7) [44.1, 66.9]” | “7 (9.1) [3.7, 17.8]” |
| Time to objective response (months), median (range) | “8.2 (2.6–28.0)” | “16.7 (8.1–30.2)” |
| Duration of response (months), median (95% CI), Kaplan-Meier estimate | “NE (NE, NE)” | “NE (NE, NE)” |
| Complete response (CR) | “3 (3.8)” | “1 (1.3)” |
| Partial response (PR) | “41 (51.9)” | “6 (7.8)” |
| Stable disease (SD) | “32 (40.5)” | “59 (76.6)” |
| Progressive disease (PD) | “0” | “10 (13.0)” |
| Not available | “3 (3.8)” | “1 (1.3)” |

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.8.3-9"></a>

###### Objective response rate rounded to whole percentages

> “The confirmed objective response rate (ORR) based on RECIST v1.1 was 56% with varegacestat vs. 9% with placebo (p<0.0001), as assessed by blinded independent central review.”

Source: [Immunome press release, RINGSIDE topline results (2025)](https://investors.immunome.com/immunome-announces-positive-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors/)

<a id="topic-3.1.1.8.3-10"></a>

###### Time to response among responders

> “Among responders treated with varegacestat, median time to response was 8.2 months (range: 2.6-28.0 months) vs. 16.7 months (range: 8.1-30.2 months) for responders receiving placebo.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="topic-3.1.1.8.3-11"></a>

###### Key secondary endpoint: change in tumor volume at Week 24

> “Varegacestat: -109.6 (40.64)”
> “Placebo +122.8 (42.72)”
> “Difference: −232.4 (57.39), P<0.0001”
> “Least-squares mean (standard error)”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.8.3-12"></a>

###### Tumor volume measured by T2-weighted MRI or CT

> “Measured by T2 weighted MRI or CT per BICR”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-3.1.1.8.3-13"></a>

###### Median best percent change in tumor volume

> “Median best percent change: −83% (range: −100 to 55)”
> “Median best percent change: +11% (range: −100 to 199)”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “In an exploratory analysis, varegacestat demonstrated a median best change in tumor volume of -83% vs. +11% with placebo, as assessed by blinded independent central review.”

Source: [Immunome press release, RINGSIDE topline results (2025)](https://investors.immunome.com/immunome-announces-positive-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors/)

<a id="topic-3.1.1.8.3-14"></a>

###### T2-weighted MRI signal intensity: descriptive analysis

> “T2-Weighted Signal Intensity Reduction”
> “Median best percent change: varegacestat -100% vs placebo -12%”
> “Change from baseline in RECIST sum of diameters (SOD), TV, and T2W signal intensity”

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### Key secondary endpoint: GODDESS worst pain intensity at Week 12

> “Varegacestat: −2.24 (0.27)”
> “Placebo: +0.18 (0.27)”
> “Difference: −2.42 (0.37), P<0.0001”
> “Clinically significant difference (>2 points) in favor of varegacestat as early as first evaluation at Week 4”
> “Assessed with the Gounder/Desmoid Tumor Research Foundation Desmoid Tumor Symptom/Impact Scale”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “At week 12, patients treated with varegacestat experienced a mean change from baseline of -2.24 (standard error [SE]: 0.27) compared with +0.18 (SE: 0.27) for patients receiving placebo, for a treatment difference of -2.42 (SE: 0.37; p<0.0001).”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="topic-3.1.1.8.4-2"></a>

###### Exploratory PRO endpoints: GODDESS and PROMIS Physical Function 10a

> “Select PRO Exploratory Endpoints:”
> “Change from baseline in pain and DT symptoms (GODDESS)”
> “Change from baseline in Physical Functioning (PROMIS Physical Functioning 10a)”
> “Completed as a daily diary for 7 days (scores averaged over the 7 days), at baseline and every 4 weeks”
> “Completed once at baseline and every 4 weeks”
> “Analyses on ITT population; symptoms at baseline were not an enrollment criterion”
> “Clinically meaningful thresholds were derived from the RINGSIDE population”

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

<a id="topic-3.1.1.8.4-3"></a>

###### GODDESS DTSS pain domain score: least-squares mean difference by week

| Analysis visit | Varegacestat participants with data | Placebo participants with data | Difference, varegacestat vs placebo |
| --- | --- | --- | --- |
| Week 12 | “52” | “55” | “Diff: -2.32” |
| Week 24 | “47” | “43” | “Diff: -2.02” |
| Week 48 | “37” | “27” | “Diff: -2.70” |

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

> “Change in DTSS Pain Domain Score† (worst pain, dull pain, shooting pain)”
> “clinically meaningful improvement = -1.62”
> “Nominal p <0.05”
> “Least-square (LS) means derived from mixed model for repeated measures (MMRM)”

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

<a id="topic-3.1.1.8.4-4"></a>

###### GODDESS DTSS TSS-5 symptom score: least-squares mean difference by week

| Analysis visit | Varegacestat participants with data | Placebo participants with data | Difference, varegacestat vs placebo |
| --- | --- | --- | --- |
| Week 12 | “52” | “55” | “Diff: -1.46” |
| Week 24 | “47” | “43” | “Diff: -1.43” |
| Week 48 | “37” | “27” | “Diff: -2.09” |

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

> “Pain intensity, fatigue, swelling, muscle weakness, difficulty moving”
> “clinically meaningful improvement = -1.16.”

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

<a id="topic-3.1.1.8.4-5"></a>

###### GODDESS TSS-5 symptom score at week 48, ESMO 2026 press release

> “At week 48, patients treated with varegacestat had a least-squares mean change from baseline in the GODDESS TSS-5 symptom score of -1.50 vs. +0.59 for patients receiving placebo, with lower scores indicating lower symptom burden.”

Source: [Immunome press release, ESMO 2026 data (2026)](https://investors.immunome.com/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026/)

<a id="topic-3.1.1.8.4-6"></a>

###### PROMIS Physical Function 10a T-score: least-squares mean difference by week

| Analysis visit | Varegacestat participants with data | Placebo participants with data | Difference, varegacestat vs placebo |
| --- | --- | --- | --- |
| Week 12 | “54” | “60” | “Diff: +3.13” |
| Week 24 | “47” | “45” | “Diff: +5.84” |
| Week 48 | “37” | “26” | “Diff: +6.54” |

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

> “clinically meaningful improvement = +3.10”
> “Baseline was originally defined as the last assessment before randomization and was redefined post hoc to include PRO assessments completed on or before first dose.”
> “Results shown use this updated baseline definition and remained consistent with the primary week 12, 24, and 48 findings.”

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

<a id="topic-3.1.1.8.4-7"></a>

###### PROMIS Physical Function at week 48, ESMO 2026 press release

> “On the PROMIS Physical Function measure, where higher scores indicate better function, the least-squares mean change from baseline was +3.90 with varegacestat vs. -3.04 with placebo at week 48.”

Source: [Immunome press release, ESMO 2026 data (2026)](https://investors.immunome.com/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026/)

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Overall adverse event summary, ASCO 2026 abstract

> “Overall, 95% of adverse events (AEs) were Grade 1-2 and there were no Grade 5 AEs.”
> “Grade 3/4 AEs were reported in 57% of VAR pts and 17% of PBO pts.”
> “AEs led to dose reduction in 63 (80%) VAR pts and 7 (9%) PBO pts; 16 (20%) VAR pts and 5 (7%) PBO pts discontinued due to AEs.”
> “In the VAR arm, the most frequently reported AEs were diarrhea (82%), fatigue (44%), and rash (43%).”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-3.1.1.8.5-2"></a>

###### Adverse events reported in 25% or more of either arm, ASCO 2026 presentation

| Adverse event (MedDRA preferred term), n (%) | Varegacestat any grade | Varegacestat grade 3+ | Placebo any grade | Placebo grade 3+ |
| --- | --- | --- | --- | --- |
| Any adverse event | “79 (100)” | “45 (57)” | “70 (91)” | “13 (17)” |
| Diarrhea | “65 (82)” | “8 (10.1)” | “21 (27)” | “0” |
| Fatigue | “35 (44)” | “1 (1.3)” | “18 (23)” | “2 (2.6)” |
| Rash | “34 (43)” | “2 (2.5)” | “9 (12)” | “0” |
| Nausea | “28 (35)” | “0” | “20 (26)” | “0” |
| Cough | “27 (34)” | “0” | “4 (5)” | “0” |
| Hypophosphatemia | “27 (34)” | “1 (1.3)” | “2 (3)” | “0” |
| Alopecia | “26 (33)” | “0” | “3 (4)” | “0” |
| Dry mouth | “24 (30)” | “0” | “5 (7)” | “0” |
| Hair color changes | “20 (25)” | “0” | “0” | “0” |
| Pruritus | “20 (25)” | “0” | “4 (5)” | “0” |
| Rash maculo-papular | “20 (25)” | “1 (1.3)” | “1 (1)” | “0” |

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “Reported in ≥25% in either arm”
> “MedDRA preferred terms”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.8.5-3"></a>

###### Most common treatment-emergent adverse events reported in 20% or more of either arm, ESMO 2026 safety poster

| Adverse event (MedDRA preferred term), n (%) | Varegacestat any grade | Varegacestat grade ≥3 | Placebo any grade | Placebo grade ≥3 |
| --- | --- | --- | --- | --- |
| Any adverse event | “79 (100)” | “45 (57)” | “70 (91)” | “13 (17)” |
| Diarrhea | “65 (82)” | “8 (10)” | “21 (27)” | “0” |
| Fatigue | “35 (44)” | “1 (1)” | “18 (23)” | “2 (2.6)” |
| Rash | “34 (43)” | “2 (3)” | “9 (12)” | “0” |
| Nausea | “28 (35)” | “0” | “20 (26)” | “0” |
| Cough | “27 (34)” | “0” | “4 (5)” | “0” |
| Hypophosphatemia | “27 (34)” | “1 (1)” | “2 (3)” | “0” |
| Alopecia | “26 (33)” | “0” | “3 (4)” | “0” |
| Dry mouth | “24 (30)” | “0” | “5 (7)” | “0” |
| Hair color changes | “20 (25)” | “0” | “0” | “0” |
| Pruritus | “20 (25)” | “0” | “4 (5)” | “0” |
| Rash maculo-papular | “20 (25)” | “1 (1)” | “1 (1)” | “0” |
| ALT increase | “18 (23)” | “3 (4)” | “4 (5)” | “0” |
| AST increase | “18 (23)” | “2 (3)” | “2 (3)” | “0” |
| Amenorrhea | “17 (22)” | “0” | “2 (3)” | “0” |
| Upper respiratory tract infection | “17 (22)” | “0” | “5 (7)” | “0” |
| Vomiting | “16 (20)” | “0” | “6 (8)” | “0” |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

> “Reported in ≥20% in either arm”
> “Population: all participants who received ≥1 dose of study drug (i.e., the intention-to-treat population).”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.8.5-4"></a>

###### Frequently reported adverse events as grouped terms, with median time to first onset

| Adverse event, n (%) | Varegacestat all grades | Varegacestat median time to onset (days) | Varegacestat grade ≥3 | Placebo all grades | Placebo median time to onset (days) | Placebo grade ≥3 |
| --- | --- | --- | --- | --- | --- | --- |
| Diarrhea | “65 (82.3)” | “14.0” | “8 (10.1)” | “21 (27.3)” | “21.0” | “0” |
| Rash (grouped term) | “56 (70.9)” | “24.0” | “4 (5.1)” | “13 (16.9)” | “69.0” | “0” |
| Fatigue (grouped term) | “46 (58.2)” | “27.5” | “1 (1.3)” | “24 (31.2)” | “19.0” | “2 (2.6)” |
| Hair follicle AEs (grouped term) | “32 (40.5)” | “59.0” | “2 (2.5)” | “3 (3.9)” | “70.0” | “0” |
| Cough (grouped term) | “31 (39.2)” | “16.0” | “1 (1.3)” | “5 (6.5)” | “198.0” | “0” |
| Nausea | “28 (35.4)” | “8.0” | “0” | “20 (26.0)” | “7.5” | “0” |
| Hypophosphatemia | “27 (34.2)” | “29.0” | “1 (1.3)” | “2 (2.6)” | “49.5” | “0” |
| Upper respiratory infection (grouped term) | “27 (34.2)” | “46.0” | “0” | “6 (7.8)” | “136.5” | “0” |
| Dry mouth | “24 (30.4)” | “13.0” | “0” | “5 (6.5)” | “8.0” | “0” |
| Hair color changes | “20 (25.3)” | “60.5” | “0” | “0” | | “0” |
| Ovarian toxicity (grouped term; percentage of the whole population) | “20 (25.3)” | “56.5” | “0” | “2 (2.6)” | “41.5” | “0” |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

> “denotes grouped terms comprising multiple clinically related MedDRA preferred terms”
> “calculated as a percentage of the whole population – see Ovarian Toxicity section for more details”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.8.5-5"></a>

###### Select adverse events of interest by grade, including squamous cell carcinoma and keratoacanthoma

| Adverse event of interest | Varegacestat grade 1 | Varegacestat grade 2 | Varegacestat grade 3 | Placebo grade 1 | Placebo grade 2 | Placebo grade 3 |
| --- | --- | --- | --- | --- | --- | --- |
| Diarrhea | “43.0%” | “29.1%” | “10.1%” | “23.4%” | “3.9%” | |
| Rash (grouped terms) | “36.7%” | “29.1%” | “5.1%” | “14.3%” | “2.6%” | |
| Ovarian toxicity | | “25.3%” | | | “2.6%” | |
| Squamous cell carcinoma and keratoacanthoma | “1.3%” | “6.3%” | “1.3%” | | | “1.3%” |
| Elevated liver enzymes (ALT or AST grade 2 or higher) | | “3.8%” | “3.8%” | | “2.6%” | |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

> “Among these AEs, the most frequently reported were diarrhea and rash, which were primarily grade 1-2”
> “Defined as alanine aminotransferase or aspartate aminotransferase with grade ≥2 per Common Terminology Criteria for Adverse Events (CTCAE) v5.0”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.8.5-6"></a>

###### Serious adverse events and deaths

> “No deaths due to adverse events”
> “Serious adverse events: Varegacestat: 25 pts (32%) | Placebo: 7 pts (9%)”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

> “There were no deaths on study”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

> “There were no deaths on study”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-3.1.1.8.5-7"></a>

###### Alopecia by grade

> “Of 26 patients reporting alopecia, 25 were Grade 1”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “Of 26 varegacestat participants reporting alopecia, 25 had Grade 1 and one had Grade 2 attributed to another drug associated with alopecia”

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

<a id="topic-3.1.1.8.5-8"></a>

###### Dose reductions, ASCO 2026 presentation

> “Varegacestat 80% | Placebo 9%”
> “Varegacestat 3.5 months | Placebo 5.6 months”
> “Most common reason: diarrhea 19%”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.8.5-9"></a>

###### Dose levels and time to first dose reduction or interruption

> “1.2 mg once daily”
> “0.9 mg once daily”
> “0.6 mg once daily”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

| Measure | Varegacestat | Placebo |
| --- | --- | --- |
| Median time to first dose reduction to 0.9 mg | “to 0.9 mg (n=60): 3.7 (IQR 1.8, 8.3) months” | “to 0.9 mg (n=7): 5.6 (IQR 2.1, 16.1) months” |
| Median time to first dose reduction to 0.6 mg | “to 0.6 mg (n=36): 7.3 (IQR 3.0, 12.5) months” | “to 0.6 mg (n=2): 10.7 (IQR 4.9, 16.6) months” |
| Median time to first dose interruption | “Varegacestat (n=63): 2.5 (IQR 1.0, 5.7) months” | “Placebo (n=29): 3.4 (IQR 1.9, 7.3) months” |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.8.5-10"></a>

###### Adverse events leading to dose reduction

> “Dose Reduction”
> “Varegacestat 80% | Placebo 9%”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

| Preferred term, n (%) | Varegacestat (n=79) | Placebo (n=77) |
| --- | --- | --- |
| Diarrhea | “15 (19.0)” | “0” |
| Fatigue | “7 (8.9)” | “1 (1.3)” |
| Rash | “7 (8.9)” | “0” |
| Rash maculo-papular | “6 (7.6)” | “0” |
| Folliculitis | “4 (5.1)” | “0” |
| Hidradenitis | “4 (5.1)” | “0” |
| ALT increased | “3 (3.8)” | “0” |
| Cough | “3 (3.8)” | “1 (1.3)” |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.8.5-11"></a>

###### Adverse events leading to dose interruption

> “Varegacestat 65% | Placebo 14%”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

| Preferred term, n (%) | Varegacestat (n=79) | Placebo (n=77) |
| --- | --- | --- |
| Diarrhea | “9 (11.4)” | “1 (1.3)” |
| Fatigue | “6 (7.6)” | “0” |
| Rash | “6 (7.6)” | “0” |
| Vomiting | “5 (6.3)” | “1 (1.3)” |
| ALT increased | “4 (5.1)” | “2 (2.6)” |
| Pyrexia | “4 (5.1)” | “1 (1.3)” |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.8.5-12"></a>

###### Adverse events leading to discontinuation

> “Varegacestat 20% | Placebo 7%”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

| Preferred term, n (%) | Varegacestat (n=79) | Placebo (n=77) |
| --- | --- | --- |
| Fatigue | “2 (2.5)” | “1 (1.3)” |
| Hidradenitis | “2 (2.5)” | “0” |
| Hyperthyroidism | “2 (2.5)” | “0” |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

> “Varegacestat 20% | Placebo 7%”
> “Reasons varied with no events in >2.6%”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “Discontinuation Due to AEs: Varegacestat 20% | Placebo 6%”
> “Reasons varied with no single event in >2 participants”

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

<a id="topic-3.1.1.8.5-13"></a>

###### Ovarian toxicity in premenopausal women

> “Ovarian toxicity occurred in 20/36 (56%) premenopausal women on VAR, resolved in 11/20 (55%), and did not lead to dose interruption or drug withdrawal.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “A known class effect of GSI”
> “Varegacestat 56% | Placebo 5%”
> “Resolved in 55% of those who reported it”
> “No discontinuations for ovarian toxicity”
> “Ovarian toxicity includes the MedDRA preferred terms amenorrhea, premature menopause, menopause, ovarian failure”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “55.6% of premenopausal women experienced ovarian toxicity”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

> “20 of 36 (56%) of premenopausal women experienced ovarian toxicity, which resolved in 11 of 20 patients (55%)”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-3.1.1.8.5-14"></a>

###### Ovarian toxicity resolution by treatment disposition

> “Resolution by treatment disposition – data cutoff Oct 7, 2025”
> “20 of 36 premenopausal women with ovarian toxicity (56%)”
> “8 off varegacestat, follow-up available”
> “OT resolved in 8 (100%)”
> “10 ongoing varegacestat”
> “OT resolved in 3 (30%)”
> “OT unresolved in 7 (70%)”
> “2 off study, no follow-up available”
> “No women discontinued varegacestat due to ovarian toxicity”
> “Ovarian toxicity resolved in all participants with follow-up data after stopping treatment”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.8.5-15"></a>

###### Most common adverse events by arm, rounded to whole percentages

> “The most common adverse events for participants in the treatment arm as opposed to the placebo arm were diarrhea (82% vs. 27%), fatigue (44% vs. 23%), rash (43% vs. 12%), nausea (35% vs. 26%) and cough (34% vs. 5%).”
> “Most (95%) adverse events were grade 1 or 2.”
> “Dose reductions due to treatment-emergent adverse events occurred in 80% of patients treated with varegacestat vs. 9% with placebo.”
> “Treatment discontinuations due to adverse events occurred in 20% of patients treated with varegacestat vs. 7% with placebo.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

- Part B results are available only as an ASCO 2026 meeting abstract and oral presentation, ESMO 2026 presentations, and Immunome press releases and investor presentations. The abstract states that it “does not include a full text component”. The ClinicalTrials.gov record (primary completion December 3, 2025; status active, not recruiting) lists no posted results, and no registry protocol or statistical analysis plan is available for comparison with the reported analyses. The study was “sponsored/funded by Immunome and Ayala Pharmaceuticals, Inc.”.
- The comparator is placebo. No trial has compared varegacestat with nirogacestat, the approved gamma secretase inhibitor; Immunome's cross-trial response rate chart states that “no head-to-head clinical trial has been conducted”.
- Crossover to the open-label extension was allowed from either arm at progression, and the open-label extension is ongoing. Median exposure was 20.3 months with varegacestat and 11.1 months with placebo, so cumulative adverse event frequencies are compared over unequal exposure.
- At the October 7, 2025 data cutoff, 7 of 79 varegacestat participants and 29 of 77 placebo participants had a PFS event; median PFS was not estimable and median duration of response was not reached with varegacestat, which limits the precision of the hazard ratio and of the 2-year landmark estimates.
- The ASCO presentation labels a “Post-hoc subgroup analysis to evaluate patients with poor prognosis”; the subgroups shown include age 30 years or younger, CTNNB1 mutation, and baseline tumor size above 10 cm, and the abstract states only that PFS “consistently favored VAR in all subgroups analyzed”.
- Baseline imbalances include intra-abdominal target tumors (24.1% with varegacestat and 36.4% with placebo), any prior therapy (65.8% and 77.9%), and prior surgery (30.4% and 42.9%); the placebo arm's target tumor size range extends to 666.3 mm.
- Dose reductions due to adverse events occurred in 80% of varegacestat participants (to 0.9 mg in 60 and to 0.6 mg in 36), and dose interruptions in 65%. The efficacy results therefore reflect a 1.2 mg starting dose with frequent reduction, and the dose intensity actually delivered has not been reported.
- The symptom, pain domain, and physical function analyses are exploratory, with nominal p values. Completion declined over time: at week 48, pain and symptom data were available for 37 varegacestat and 27 placebo participants, against 52 and 55 at week 12. The PROMIS Physical Function baseline was “redefined post hoc”. Characteristic adverse events (diarrhea in 82% versus 27%, alopecia in 33% versus 4%, hair color changes in 25% versus 0%) may have allowed participants to infer their assignment, which could bias patient-reported outcomes in a double-blind trial.
- Figures differ between sources. The PFS hazard ratio's 95% CI is 0.07 to 0.38 in the abstract and slides and 0.071 to 0.375 in Immunome releases. ORR is 55.7% versus 9.1% in the abstract and slides and 56% versus 9% in releases. Placebo discontinuation due to adverse events is 7% in the abstract, ASCO slides, and safety poster and 6% in the primary results poster. Premenopausal women are 45.6% of the varegacestat arm in one table and 67.9% of its female participants in another. Rash is 43% as a preferred term and 70.9% as a grouped term. Death is reported as “No deaths due to adverse events” in the ESMO safety poster and as “There were no deaths on study” in the investor presentations. Ovarian toxicity resolved in 55% overall but in all 8 participants with follow-up off treatment. Week 48 PROMIS Physical Function is reported as +3.90 versus −3.04 in the ESMO press release, while the presentation, using the redefined baseline, reports a difference of +6.54.

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506); [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf); [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf); [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf); [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf); [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282); [Immunome press release, RINGSIDE topline results (2025)](https://investors.immunome.com/immunome-announces-positive-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors/); [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/); [Immunome press release, ESMO 2026 data (2026)](https://investors.immunome.com/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026/); [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf); [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="heading-3.1.2"></a>

#### 3.1.2 RINGSIDE Part A

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Study purpose: safety, preliminary efficacy, and selection of the phase III dose regimen

> “We report results of the phase II open-label, multicenter, randomized, dose-finding study to evaluate safety and preliminary efficacy and select a phase III dose regimen.”
> “What is the optimal dose regimen of oral varegacestat in adults with progressing desmoid tumors, based on safety and antitumor activity?”
> “We evaluated three varegacestat dose regimens in adults with progressing DTs.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.1-2"></a>

###### Registry objective

> “The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.2.1-3"></a>

###### Post hoc analysis objective: treatment response in key subgroups

> “We evaluated treatment response in key subgroups.”

Source: [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516)

<a id="topic-3.1.2.1-4"></a>

###### Exploratory analysis objective: T2-weighted signal intensity, tumor volume, and exposure-response

> “We report exploratory analyses of T2W signal intensity, tumor volume and exposure-response (E-R) in the RINGSIDE Phase 2 study”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Screening and enrollment from October 2021 to July 2022 at 21 academic medical centers in seven countries

> “Between October 6, 2021, and July 15, 2022, 52 participants were screened, of whom 42 were enrolled (14 in each dose arm) at 21 academic medical centers in Australia, Korea, Spain, Israel, the Netherlands, the United Kingdom, and the United States (Fig 1).”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.2-2"></a>

###### Transition to the open-label extension from October 2022 to May 2023 and data as of January 6, 2025

> “Between October 4, 2022, and May 30, 2023, 29 (69.0%) participants transitioned to the open-label extension, where all received 1.2 mg once daily. As of January 6, 2025, 12 participants remained on treatment.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.2-3"></a>

###### Study start and data cutoff

> “Study start: Oct. 6, 2021 | Data cutoff: Jan. 6, 2025”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-3.1.2.2-4"></a>

###### Enrollment completed as of March 2022 and interim data as of January 3, 2023

> “Enrollment of all 42 patients into Phase 2 was completed as of March 2022. As of January 3, 2023, median time on study was 10.5 months (range 0.8 – 14.7) and 30 patients (71.4%) were still on study, 10 (23.8%) of whom rolled over to the OLE.”

Source: [Gounder et al. (2023b)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.11515)

<a id="topic-3.1.2.2-5"></a>

###### Interim data as of April 10, 2024

> “As of April 10, 2024, median time on treatment was 25.4 mo (range 1 – 29); 21 pts (50%) were still on treatment.”

Source: [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857)

<a id="topic-3.1.2.2-6"></a>

###### Registry dates and study identifier

| Field | Quoted record |
| --- | --- |
| First posted | “2021-05-04” |
| Study start (actual) | “2021-09-01” |
| Other study ID | “AL-DES-01” |

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Open-label, randomized, dose-finding phase II part of a phase II/III trial

> “RINGSIDE phase II was an open-label, randomized, dose-finding trial of varegacestat in adults with histologically confirmed DT and disease progression.”
> “RINGSIDE was a phase II/III clinical trial (ClinicalTrials.gov identifier: NCT04871282) to evaluate the safety and efficacy of varegacestat (Immunome, Inc, Bothell, WA) for treatment of progressing DTs.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.3-2"></a>

###### Registry design: Part A dose regimen finding and Part B placebo-controlled study

> “This is a Phase 2/3, randomized study in subjects with progressive desmoid tumors consisting of 2 parts. Phase2/Part A is an open-label, dose regimen finding study; Phase3/Part B is a double blind, placebo-controlled study and Open Label Extension utilizing the dose regimen selected in Phase2/Part A.”
> “RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.2.3-3"></a>

###### Dose selection after the last week 16 MRI and entry into the open-label extension

> “Phase III dose selection was based on emerging safety and tolerability data after the last patient completed the week 16 magnetic resonance imaging (MRI) scan, and the key secondary end point of volume change could be assessed. After phase III dose selection, participants could enter an open-label extension study, where all received the selected phase III dose.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.3-4"></a>

###### Independent data monitoring committee

> “An independent data monitoring committee reviewed safety parameters at regular intervals and efficacy data to assess benefit/risk and approved the selected dose.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.3-5"></a>

###### Seamless phase 2/3 design

> “Based on these data and responses demonstrated with other GSIs, Ayala designed a seamless Phase 2/3 study called RINGSIDE to specifically evaluate the activity of varegacestat in participants with progressing desmoid tumors who required therapy.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-3.1.2.3-6"></a>

###### MRI schedule in the phase 2 part and the open-label extension

> “Scans at week 16 and every 12 weeks thereafter”
> “Scans every 12 weeks”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-3.1.2.3-7"></a>

###### Transition to the open-label extension between week 36 and week 76

> “Week 36–76”
> “Open-label Extension (OLE) (N=29)”

Source: [Bui et al. (2025)](https://dtrf.org/wp-content/uploads/2025/12/UNBRANDED_CTOS_2025_RINGSIDE-A_Subgroups_POS_final.pdf)

<a id="topic-3.1.2.3-8"></a>

###### Sponsors: Immunome and Ayala Pharmaceuticals

> “Supported by Immunome, Inc.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

> “The RINGSIDE study (NCT04871282) was sponsored/funded by Immunome and Ayala Pharmaceuticals, Inc.”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Inclusion criteria: adults with histologically confirmed, progressing desmoid tumors

> “Eligible participants were 18 years and older with histologically confirmed DTs and investigator-assessed disease progression, defined as unidimensional growth of ≥10% (sum of diameters of target lesion[s]) within 18 months of the screening MRI or DT-related pain not adequately controlled with nonopioid medication. Participants were either treatment-naïve or previously treated with at least one measurable lesion amenable to volume measurements by MRI.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.4-2"></a>

###### Registry inclusion criteria for Part A

> “Inclusion Criteria Part A:”
> “At least 18 years of age (inclusive) at the time of signing the informed consent form (ICF).”
> “Disease progression, assessed locally by the investigator, defined as having at least one of the following:”
> “Unidimensional growth of desmoid tumor(s) by ≥10%, using the sum of the largest diameters of target lesion(s), within 18 months of the screening MRI”
> “Having desmoid tumor-related pain that is not adequately controlled with nonopioid medication”
> “At least 1 measurable lesion amenable to volume measurements by MRI at screening”
> “Treatment naïve subjects for whom, in the opinion of the investigator, the IP is deemed appropriate, OR”
> “Recurrent/refractory disease following at least one line of therapy (including surgery, radiation, or systemic therapy)”
> “Must be able to swallow whole capsules with no GI condition affecting absorption; nasogastric or G-tube administration is not allowed.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.2.4-3"></a>

###### Exclusion criteria

> “Exclusion criteria included malignancy diagnosed in the past 2 years (exceptions defined in the protocol), Eastern Cooperative Oncology Group performance status ≥2, GI disease associated with diarrhea, currently or within 2 months before the first study dose, prior use of GSIs or other Notch-targeted agents, or any DT treatment within 4 weeks of screening.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.4-4"></a>

###### Registry exclusion criteria for Parts A and B: cardiac, laboratory, and prior treatment

> “Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥450 msec.”
> “Uncontrolled triglyceride ≥Grade 2 elevations per common terminology criteria for adverse events (CTCAE) v5.0 (>300 mg/dL or >3.42 mmol/L).”
> “Systemic therapy including chemotherapy, biologic (anti-neoplastic agent, antibodies), TKIs (e.g., sorafenib, pazopanib, imatinib), hormonal therapy, or investigational therapy”
> “Chronic NSAIDs for the treatment of desmoid tumors within 4 weeks of first dose of IP”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.2.4-5"></a>

###### Open-label extension inclusion and exclusion criteria

> “Participated in Part A (including MRI at Week 16) and were still on study at time that Part B/OLE dose selection was made, OR”
> “Any participant with an ongoing TEAE (including abnormal laboratory results) from Part A or Part B that requires discontinuation from the study, will not be eligible to enter the open-label extension.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Randomization 1:1:1 to 1.2 mg once daily, 2 mg intermittent, or 4 mg intermittent

> “Participants were randomly assigned 1:1:1 to one of three oral varegacestat dose regimens: 1.2 mg once daily, 2 mg intermittent, or 4 mg intermittent (intermittent: once daily for 2 consecutive days with 5 consecutive days off).”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.5-2"></a>

###### Rationale for intermittent dosing

> “Intermittent dosing was hypothesized to improve tolerability by mitigating GI toxicity observed with daily dosing in animal models.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.5-3"></a>

###### Treatment duration and switch to 1.2 mg once daily in the open-label extension

> “Participants received varegacestat at assigned doses until disease progression, intolerable toxicity, withdrawal of consent, or initiation of the open-label extension study (ie, after the last participant completed the week 16 MRI scan and the phase III dose was selected). At that time, participants still active in phase II were eligible to enter the open-label extension, where all received the selected phase III dose (1.2 mg once daily), regardless of their prior phase II dose assignment.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.5-4"></a>

###### Treatment beyond progression

> “Participants who experienced treatment benefit could continue on varegacestat after disease progression by blinded independent central review (BICR) with approval of the sponsor's medical monitor.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.5-5"></a>

###### Registry arms of Part A and the open-label extension

> “Experimental: Part A Main Study 1.2 mg daily”
> “Experimental: Part A Main Study 2 mg Intermittent”
> “Experimental: Part A Main Study 4 mg Intermittent”
> “AL102, recommended dose regimen from Part A, 1.2 mg daily”
> “AL102 is an inhibitor of gamma secretase-mediated Notch signaling.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.2.5-6"></a>

###### Dose regimens: 2 mg and 4 mg on two days each week or 1.2 mg daily

> “The Phase 2 portion of RINGSIDE enrolled 42 participants at three different dosing regimens of varegacestat: 2 mg once a day for two days every week, 4 mg once a day for two days every week and 1.2 mg once a day daily.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary endpoint: safety based on treatment-emergent adverse events

> “The primary end point was safety of varegacestat based on treatment-emergent adverse events (AEs) coded according to the Medical Dictionary of Regulatory Activities (MedDRA) version 27.1. Investigators determined AE severity in accordance with the National Cancer Institute's Common Terminology Criteria for Adverse Events v5.0 and assessed seriousness and relatedness to the study drug.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.6.1-2"></a>

###### Registry primary outcome: frequency and severity of TEAEs and SAEs

| Outcome measure | Measure description | Time frame |
| --- | --- | --- |
| “Part A: Safety and Tolerability - Adverse Events” | “Evaluation of the safety and tolerability of AL102 in subjects with progressing desmoid tumors as defined by as defined by the frequency and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)” | “Approximately 1.5 years” |

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.2.6.1-3"></a>

###### Rationale: dose selection on safety and tolerability in a dose-finding study

> “Phase III dose selection was based on emerging safety and tolerability data after the last patient completed the week 16 magnetic resonance imaging (MRI) scan, and the key secondary end point of volume change could be assessed.”
> “Intermittent dosing was hypothesized to improve tolerability by mitigating GI toxicity observed with daily dosing in animal models.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.6.1-4"></a>

###### Adverse events of special interest: ovarian toxicity, liver enzyme elevations, and nonmelanoma skin cancers

> “Prespecified AEs of special interest were ovarian toxicity (MedDRA preferred terms amenorrhea, premature menopause, menopause, and ovarian failure), grade ≥2 elevations of ALT and AST, and nonmelanoma skin cancers.”
> “Prospectively evaluating reproductive function in GSI studies is important in the DT population with its predominance of women during childbearing years.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.6.1-5"></a>

###### Secondary endpoint: change in tumor volume from baseline to week 16 by BICR

> “The key efficacy evaluation was the secondary end point of change in tumor volume at week 16 compared with baseline, as measured by MRI and determined per BICR.”
> “Individual tumor volumes were derived using semiautomated three-dimensional segmentation by interpolating manually delineated tumor boundaries across contiguous slices and summing the segmented volumes after region-of-interest adjustments to ensure anatomic accuracy.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

| Outcome measure | Measure description | Time frame |
| --- | --- | --- |
| “Part A: Change in Tumor Volume” | “Change from baseline to Week 16 in tumor volume as measured by centrally read magnetic resonance imaging (MRI) by Blinded Independent Central Review (BICR)” | “Approximately 16 weeks” |

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.2.6.1-6"></a>

###### Rationale for volumetric MRI assessment

> “Because of nonuniform growth patterns of DT, volumetric measurements are more sensitive for early identification of response and outperform unidimensional assessment by RECIST v1.1”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

> “T2-weighted (T2W) signal intensity and tumor volume on MRI may be more sensitive than RECIST for assessing treatment effect in desmoid tumors (DTs)”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-3.1.2.6.1-7"></a>

###### Exploratory endpoints: RECIST v1.1 objective response rate, duration of response, and MRI signal biomarkers

> “Exploratory end points included ORR based on RECIST v1.1 performed both by the BICR and by the investigator, duration of response (DOR) by BICR and by the investigator, RECIST sum of diameters, T2-weighted signal intensity on MRI (an imaging biomarker to assess response and biological conversion from cellular, proliferative lesion to collagenous scar”
> “and degree of T1-weighted enhancement on postgadolinium MRI (an imaging biomarker that can help guide selection of optimal treatment strategies”
> “Baseline biopsies were assessed for CTNNB1 and APC mutations using the Tempus xT NGS assay (Tempus, Chicago, IL). Pharmacokinetic analyses evaluated varegacestat exposure across the three dose cohorts.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.6.1-8"></a>

###### Rationale for T2-weighted signal intensity as a marker of tumor cellularity

> “On T2W images, hyperintense areas are associated with active fibroblast proliferation and hypointense areas are associated with loss of tumor cells and an increase in collagenous tissue”
> “A decrease in T2 signal intensity, as measured by MRI, reflects a decrease in tumor cellularity and, in desmoid tumors, is considered an indicator of anti-tumor activity and symptomatic improvement.”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-3.1.2.6.1-9"></a>

###### Primary, secondary, and exploratory endpoints

> “Primary Endpoint: Safety”
> “Secondary Endpoint: Tumor volume reduction at Week 16”
> “Exploratory Endpoints: ORR by RECIST v1.1 and T2W signal reduction”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-3.1.2.6.1-10"></a>

###### Open-label extension endpoints in the registry

> “Open Label Extension (OLE): Safety and Tolerability”
> “OLE: Confirmed ORR”
> “Proportion of participants with confirmed ORR (CR and PR) by BICR based on RECIST v1.1”
> “OLE: PRO - GODDESS DTSS Total Symptom Score”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Sample size: 12 participants per dose regimen for 85% power

> “For the efficacy end point of change in tumor volume, 12 participants per dosing regimen provided 85% power to detect a statistically significant difference between week 16 and baseline measurements in each dosing regimen separately, assuming a standard deviation (SD) of 15 for tumor volume change (cm3), normally distributed tumor volume, an early discontinuation rate of 10%, and a t test with a two-sided alpha error of 5%.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.7.1-2"></a>

###### Participants enrolled, MRI-evaluable, and entering the open-label extension

> “In total, 42 participants enrolled in the randomized trial (14 per dose arm).”
> “Among the 37 (88.1%) MRI-evaluable participants in the randomized trial”
> “Among 29 (69%) participants who entered the open-label extension and received 1.2 mg once daily”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.7.1-3"></a>

###### Registry enrollment

| Field | Quoted record |
| --- | --- |
| Enrollment (actual) | “198” |

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.2.7.1-4"></a>

###### Evaluable population of 36 participants

> “Objective response per RECIST1 in evaluable patients (n=36)”

Source: [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857)

<a id="topic-3.1.2.7.1-5"></a>

###### Interim evaluable populations by dose regimen

> “The best response in the evaluable population as assessed by blinded independent central review (BICR) was partial response (PR) in 6/12 patients (50%) for 1.2 mg QD, 3/13 patients (23.1%) for 4 mg BIW, and 5/11 patients (45.5%) for 2 mg BIW.”

Source: [Gounder et al. (2023b)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.11515)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Safety and efficacy analysis sets

> “Safety analyses included all randomly assigned participants who received at least one dose of varegacestat. Efficacy analyses included all randomly assigned participants who received at least one dose of varegacestat, had measurable disease assessed by BICR per RECIST v1.1 at baseline, and had a valid MRI measurement of tumor volume at week 4 or later.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.7.2-2"></a>

###### Analysis of covariance of tumor volume change and confidence intervals for response

> “Analysis of covariance (ANCOVA) for least squares (LS) mean change in tumor volume, SE, and 95% CI was performed with planned treatment as a fixed effect and baseline tumor volume and age as covariates. The median percent change from baseline in tumor volume at week 16 and the median best (minimum) percent change from baseline across all visits, including week 16, were evaluated for each dose arm.”
> “Two-sided 95% CI calculated using the Clopper-Pearson Exact Method.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.7.2-3"></a>

###### Evaluable population: at least one post-baseline scan

> “Evaluable population: patients with at least 1 post-baseline scan”

Source: [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857)

<a id="topic-3.1.2.7.2-4"></a>

###### Intention-to-treat and evaluable populations

> “Overall, the ORR in evaluable participants as measured by RECIST v1.1 by an independent radiologist was 64% for all doses tested. The 1.2 mg daily dosing cohort had an ORR of 75% in the evaluable population. Among participants in the intention-to-treat population, the overall response rate was 55% across all doses tested and the response rate was 64% for participants in the 1.2 mg daily dosing cohort.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-3.1.2.7.2-5"></a>

###### Subgroup analysis set: subgroups with at least 5 participants, pooled across dose regimens

> “We performed descriptive analyses of objective response rate (ORR) in the following subgroups with at least 5 participants: age (≤40 years vs. >40 years), tumor size (<70 mm vs. ≥70 mm), prior lines of therapy (0, 1, or 2+), tumor location (intra-abdominal vs. extra-abdominal) and mutational biomarkers (APC vs CTNNB1). Subgroups were analyzed by pooling across dose regimens.”

Source: [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516)

<a id="topic-3.1.2.7.2-6"></a>

###### Post hoc imaging analysis methods

> “Descriptive analysis of T2W signal intensity, tumor volume and RECIST sum of diameters”
> “Linear correlations of best % changes from baseline on these assessments were evaluated with Pearson correlation coefficient”
> “Exposure-response modeling evaluated time course of drug effect on tumor volume to support selection of 1.2 mg once daily for further study”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Screening, enrollment, and discontinuation during the randomized trial

> “Between October 6, 2021, and July 15, 2022, 52 participants were screened, of whom 42 were enrolled (14 in each dose arm)”
> “Thirteen participants (31.0%) discontinued varegacestat for the following reasons: AE (n = 6), progressive disease (n = 3), withdrawal by the participant (n = 2), pregnancy (n = 1), and other reasons (n = 1).”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.1-2"></a>

###### Exposure by dose arm during the randomized trial

> “Median varegacestat exposure was 50.5 (range, 3.0-76.0) weeks.”
> “The median (range) duration of varegacestat exposure during the randomized trial was 48.5 (7.0-69.0) weeks for the 1.2-mg once-daily dose, 52.0 (3.0-76.0) weeks for the 2-mg intermittent dose, and 48.5 (13.0-73.0) weeks for 4-mg intermittent dose.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.1-3"></a>

###### Open-label extension: 29 participants and 12 remaining on treatment as of January 6, 2025

> “Between October 4, 2022, and May 30, 2023, 29 (69.0%) participants transitioned to the open-label extension, where all received 1.2 mg once daily. As of January 6, 2025, 12 participants remained on treatment. The median duration of varegacestat exposure was 102.0 weeks (range, 3.0-169.0) for the combined randomized trial and open-label extension periods.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.1-4"></a>

###### Time on treatment as of January 6, 2025

> “42 participants enrolled”
> “29 (69%) entered the OLE”
> “Median time on treatment: 23.3 months (range 0.7 – 38.8)”
> “12 participants (29%) still on treatment”
> “Treatment duration: median 112 weeks | maximum: 165 weeks”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-3.1.2.8.1-5"></a>

###### Time on treatment as of April 10, 2024: median 25.4 months

> “Phase II enrolled 42 pts, of whom 29 (69%) entered the OLE. As of April 10, 2024, median time on treatment was 25.4 mo (range 1 – 29); 21 pts (50%) were still on treatment.”

Source: [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857)

<a id="topic-3.1.2.8.1-6"></a>

###### Time on treatment as of April 10, 2024: median 23.1 months

> “RINGSIDE Phase 2 enrolled 42 participants, of whom 29 (69%) entered the OLE. As of April 10, 2024, median time on treatment was 23.1 months (range 0.7 – 26.6) and 23 participants (55%) were still on treatment.”

Source: [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516)

<a id="topic-3.1.2.8.1-7"></a>

###### Time on study as of January 3, 2023

> “As of January 3, 2023, median time on study was 10.5 months (range 0.8 – 14.7) and 30 patients (71.4%) were still on study, 10 (23.8%) of whom rolled over to the OLE.”

Source: [Gounder et al. (2023b)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.11515)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Age, sex, mutation status, and prior therapy

> “Participant characteristics included 69.0% with prior systemic therapy, 47.6% with known CTNNB1 mutation, and 21.4% with known APC mutation (Table 1). The mean participant age was 39.9 (SD, 13.23) years, and 31 (73.8%) were female.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.2-2"></a>

###### Demographic and clinical characteristics by dose arm

| Characteristic | 1.2 mg once daily (n = 14) | 2 mg intermittent (n = 14) | 4 mg intermittent (n = 14) | All doses (N = 42) |
| --- | --- | --- | --- | --- |
| Age, years, mean (SD) | “42.1 (11.32)” | “37.8 (14.76)” | “39.9 (13.99)” | “39.9 (13.23)” |
| Female, No. (%) | “11 (78.6)” | “9 (64.3)” | “11 (78.6)” | “31 (73.8)” |
| Women of childbearing potential, No. (%) | “9 (64.3)” | “7 (50.0)” | “7 (50.0)” | “23 (54.8)” |
| Intra-abdominal tumor at screening, No. (%) | “3 (21.4)” | “4 (28.6)” | “3 (21.4)” | “10 (23.8)” |
| Tumor volume at baseline by BICR, cm3, mean (SD) | “83.93 (92.280)” | “189.17 (368.846)” | “166.91 (211.038)” | “146.05 (242.664)” |
| CTNNB1 mutation, No. (%) | “8 (57.1)” | “4 (28.6)” | “8 (57.1)” | “20 (47.6)” |
| APC mutation, No. (%) | “2 (14.3)” | “5 (35.7)” | “2 (14.3)” | “9 (21.4)” |
| Prior systemic therapy, No. (%) | “9 (64.3)” | “13 (92.9)” | “7 (50.0)” | “29 (69.0)” |
| Prior surgery, No. (%) | “7 (50.0)” | “8 (57.1)” | “4 (28.6)” | “19 (45.2)” |
| Prior radiation therapy, No. (%) | “1 (7.1)” | “2 (14.3)” | “1 (7.1)” | “4 (9.5)” |
| Unidimensional tumor growth by ≥10% within 18 months of screening, No. (%) | “11 (78.6)” | “14 (100.0)” | “10 (71.4)” | “35 (83.3)” |
| Tumor-related pain not adequately controlled with nonopioid medicine, No. (%) | “5 (35.7)” | “5 (35.7)” | “5 (35.7)” | “15 (35.7)” |

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.2-3"></a>

###### Median age, performance status, and median baseline tumor volume

| Characteristic | 1.2 mg once daily (n=14) | All doses (N=42) |
| --- | --- | --- |
| Age (years), median (min, max) | “44.0 (24, 61)” | “38.5 (19, 72)” |
| ECOG performance status 0, n (%) | “14 (100.0)” | “35 (83.3)” |
| ECOG performance status 1, n (%) | “0” | “7 (16.7)” |
| Intra-abdominal tumor at initial diagnosis, n (%) | “5 (35.7)” | “12 (28.6)” |
| Extra-abdominal tumor at initial diagnosis, n (%) | “9 (64.3)” | “30 (71.4)” |
| Tumor volume at baseline (cm3), median (min, max) | “46.30 (1.4, 244.9)” | “65.10 (1.4, 1270.3)” |

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-3.1.2.8.2-4"></a>

###### Median baseline tumor size by BICR

> “Tumor size at baseline by BICR, (mm)”
> “(17.0, 156.2)”

Source: [Bui et al. (2025)](https://dtrf.org/wp-content/uploads/2025/12/UNBRANDED_CTOS_2025_RINGSIDE-A_Subgroups_POS_final.pdf)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Tumor volume change at week 16 by dose arm

> “Among the 37 (88.1%) MRI-evaluable participants in the randomized trial, the median tumor volume reduction 16 weeks after starting 1.2 mg once daily (–51.91%) was numerically greater than that in the 2-mg (–15.25%) and 4-mg (–9.50%) intermittent regimens. In ANCOVA of LS mean tumor volume change from baseline to week 16, the reduction was statistically significant for the 1.2-mg once-daily dose (–39.8% [95% CI, –66.2 to –13.4]) but not for the 2-mg (–21.7% [95% CI, –52.0 to 8.6]) and 4-mg (–17.8% [95% CI, –43.2 to 7.6]) intermittent regimens.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.3-2"></a>

###### Median best percent change by dose arm during the randomized trial

> “The median best percent change from baseline was largest for 1.2 mg once daily based on tumor volume (–86.9%, –51.2%, and –63.4%), sum of diameters (–33.6%, –24.4%, and –26.3%), T2-weighted signal intensity (–90.0%, –53.4%, and –62.9%), and T1-weighted enhancement (–86.2%, –33.2%, and –54.2%; Fig 2).”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.3-3"></a>

###### Confirmed objective response rate during the randomized trial

> “During the randomized trial, the confirmed ORR by RECIST v1.1 was 35.7% (five partial responses) for the 1.2-mg once-daily dose, 21.4% (three partial responses) for the 2-mg intermittent dose, and 21.4% (three partial responses) for the 4-mg intermittent dose (Table 3, upper half). The median time to response was 30.0, 40.3, and 51.0 weeks, respectively, and the Kaplan-Meier estimate of median DOR was not estimable. A total of 23 participants (54.8%) had stable disease (6, 10, and 7 participants, respectively).”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.3-4"></a>

###### Tumor response by BICR per RECIST v1.1 during the randomized trial

| Response | 1.2 mg once daily (n = 14) | 2 mg intermittent (n = 14) | 4 mg intermittent (n = 14) | All doses (N = 42) |
| --- | --- | --- | --- | --- |
| Partial response, No. (%) | “5 (35.7)” | “3 (21.4)” | “3 (21.4)” | “11 (26.2)” |
| Stable disease, No. (%) | “7 (50.0)” | “6 (42.9)” | “10 (71.4)” | “23 (54.8)” |
| Progressive disease, No. (%) | “0” | “2 (14.3)” | “0” | “2 (4.8)” |
| Not available, No. (%) | “2 (14.3)” | “3 (21.4)” | “1 (7.1)” | “6 (14.3)” |
| Objective response 95% CI | “12.8 to 64.9” | “4.7 to 50.8” | “4.7 to 50.8” | “13.9 to 42.0” |
| Time to objective response, weeks, median (min, max) | “30.00 (17.3, 40.9)” | “40.29 (38.3, 41.0)” | “51.00 (40.3, 53.7)” | “40.29 (17.3, 53.7)” |

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.3-5"></a>

###### Selection of 1.2 mg once daily for phase III

> “The 1.2-mg once-daily regimen was selected for phase III based on faster and larger decreases in tumor volume, sum of diameters, and T2-weighted signal intensity (Fig 3) and higher ORR than the intermittent regimens, with consistent safety and tolerability across all doses tested.”
> “The largest responses were seen with the 1.2-mg once-daily dose, which was selected for the RINGSIDE phase III trial.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.3-6"></a>

###### Pharmacokinetic exposure by dose regimen

> “Across all three regimens stratified by dose and visit, the median Tmax for varegacestat ranged from 1 to 2 hours postdose. The geometric mean plasma Cmax ranged from 10.9 to 19.6 ng/mL, from 11.9 to 24.3 ng/mL, and from 17.8 to 24.2 ng/mL across dose cohorts at week 0 day 1, week 0 day 2, and week 8 day 1, respectively (Appendix Table A2).”
> “The geometric mean week 8 day 1 to week 0 day 1 accumulation ratio for Cmax was 1.33, 1.71, and 1.19 for 1.2-mg once-daily, 2-mg intermittent, and 4-mg intermittent doses, respectively.”
> “Varegacestat exposure was comparable across the three regimens; however, response with the once-daily regimen suggests sustained exposure above a target threshold leading to better overall efficacy, indicative of the higher ORR observed, with a manageable toxicity profile.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.3-7"></a>

###### Open-label extension: tumor volume, sum of diameters, and T2-weighted signal by original dose arm

> “The median best percent changes from baseline by original randomized dose regimen, respectively, were –88.1%, –69.5%, and –88.9% for tumor volume, –51.9%, –34.9%, and –51.5% for sum of diameters, and –95.4%, –92.5%, and –97.0% for T2-weighted signal intensity.”
> “Among 29 (69%) participants who entered the open-label extension and received 1.2 mg once daily (median exposure, 102.0 [range, 3.0-169.0] weeks), the median best percent tumor volume change was –85.88% and the confirmed ORR increased to 57.1%.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.3-8"></a>

###### Open-label extension: confirmed objective response rate of 57.1%

> “During the open-label extension, 11 additional participants achieved a partial response and two achieved a complete response, resulting in 24 total responders for an overall ORR of 57.1%. The confirmed ORR increased from 35.7% to 57.1% in the original 1.2-mg once-daily arm, 21.4% to 50.0% in the original 2-mg intermittent arm, and 21.4% to 64.3% in the original 4-mg intermittent arm (Table 3, lower half). The median time to response was 37.7, 40.6, and 63.0 weeks, respectively, and the Kaplan-Meier estimate of median DOR was not reached across all original dose arms. Eleven participants (26.2%) continued to have stable disease.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.3-9"></a>

###### Tumor response by BICR per RECIST v1.1 in the randomized trial and open-label extension combined

| Response | Original 1.2 mg once daily (n = 14) | Original 2 mg intermittent (n = 14) | Original 4 mg intermittent (n = 14) | All (N = 42) |
| --- | --- | --- | --- | --- |
| Complete response, No. (%) | “0” | “1 (7.1)” | “1 (7.1)” | “2 (4.8)” |
| Partial response, No. (%) | “8 (57.1)” | “6 (42.9)” | “8 (57.1)” | “22 (52.4)” |
| Objective response, No. (%) | “8 (57.1)” | “7 (50.0)” | “9 (64.3)” | “24 (57.1)” |
| Objective response 95% CI | “28.9 to 82.3” | “23.0 to 77.0” | “35.1 to 87.2” | “41.0 to 72.3” |
| Time to objective response, weeks, median (min, max) | “37.71 (17.3, 65.1)” | “40.57 (28.1, 101.6)” | “63.00 (40.3, 121.3)” | “51.50 (17.3, 121.3)” |
| Duration of response, weeks, median (95% CI) | “NE (46.1 to NE)” | “NE (24.9 to NE)” | “NE (NE to NE)” | “NE (NE to NE)” |

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.3-10"></a>

###### Exploratory imaging analysis: correlations and week 16 changes

> “A total of 25 responses were observed, of which one PR was unconfirmed”
> “T2W and volume demonstrated positive correlation with sum of diameters (R=0.67 and R=0.81, respectively)”
> “T2W and volume were highly correlated (R=0.93)”
> “Overall, median % changes at Week 16 were -8% by sum of diameters, -39% by T2W, and -24% by tumor volume”
> “Substantial early and rapid reductions in T2W signal intensity and tumor volume on MRI preceded subsequent varegacestat responses by RECIST in adults with DT”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-3.1.2.8.3-11"></a>

###### Exposure-response modeling: predicted median time to 30% tumor volume decrease of 3 months with 1.2 mg once daily

> “Predicted median time to 30% decrease in tumor volume was 3 months with the 1.2 mg once daily regimen”
> “Exploratory exposure-response modelling suggested that 1.2 mg once daily dose achieves earlier and deeper response than the other dose regimens”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-3.1.2.8.3-12"></a>

###### Objective response rate from 43% to 78% across subgroups

> “ORR ranged from 43% to 78% across age, tumor size, prior therapy, tumor location and mutation subgroups (Table). Response rates were comparable across all subgroups examined.”

Source: [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516)

| Subgroup | Responders, No. (%) |
| --- | --- |
| Age ≤40 years (n=22) vs. >40 years (n=14) | “13 (59) vs. 10 (71)” |
| Tumor size <70 mm (n=18) vs. ≥70 mm (n=14) | “13 (72) vs. 9 (64)” |
| Prior lines of therapy: 0 (n=11), 1 (n=16), or 2+ (n=9) | “6 (55), 10 (63), 7 (78)” |
| Intra-abdominal (n=9) vs. extra-abdominal (n=27) | “4 (44) vs. 19 (70)” |
| APC (n=7) vs CTNNB1 (n=19) mutation | “3 (43) vs. 13 (68)” |

Source: [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516)

<a id="topic-3.1.2.8.3-13"></a>

###### Objective response and duration of response by subgroup as of January 6, 2025

> “Data cutoff: Jan. 6, 2025”
> “ORR by RECIST ranged from 50% to 78%”
> “Median DOR ranged from 37.1 to 79.8 weeks”
> “Responses were seen in all subgroups examined”

Source: [Bui et al. (2025)](https://dtrf.org/wp-content/uploads/2025/12/UNBRANDED_CTOS_2025_RINGSIDE-A_Subgroups_POS_final.pdf)

| Subgroup | ORR, n (%) | DOR, weeks, median (min, max) |
| --- | --- | --- |
| All MRI-evaluable patients (n=37) | “24 (65)” | “58.9 (12.1, 120.6)” |
| Age ≤40 years (n=22) | “13 (59)” | “66.1 (22.1, 110.0)” |
| Age >40 years (n=15) | “11 (73)” | “37.1 (12.1, 120.6)” |
| Tumor size <70 mm (n=19) | “10 (53)” | “52.1 (22.1, 99.0)” |
| Tumor size ≥70 mm (n=18) | “14 (78)” | “78.4 (12.1, 120.6)” |
| Prior lines of therapy 0 (n=11) | “6 (55)” | “79.8 (22.1, 95.9)” |
| Prior lines of therapy 1 (n=13) | “9 (69)” | “37.1 (12.1, 120.6)” |
| Prior lines of therapy 2+ (n=13) | “9 (69)” | “56.0 (12.1, 110.0)” |
| Intra-abdominal (n=10) | “5 (50)” | “46.1 (12.1, 99.0)” |
| Extra-abdominal (n=27) | “19 (70)” | “61.9 (12.1, 120.6)” |
| APC mutation (n=8) | “4 (50)” | “55.4 (12.1, 66.1)” |
| CTNNB1 mutation (n=19) | “13 (68)” | “79.6 (22.1, 120.6)” |
| CTNNB1 S45F (n=3) | “2 (67)” | “31.0 (24.9, 37.1)” |
| CTNNB1 T41A (n=5) | “2 (40)” | “88.2 (55.9, 120.6)” |
| CTNNB1 other (n=11) | “9 (82)” | “82.0 (22.1, 110.0)” |

Source: [Bui et al. (2025)](https://dtrf.org/wp-content/uploads/2025/12/UNBRANDED_CTOS_2025_RINGSIDE-A_Subgroups_POS_final.pdf)

<a id="topic-3.1.2.8.3-14"></a>

###### Objective response and median best change in tumor volume in the evaluable population

> “The median best change in tumor volume and T2 signal intensity (reduced tumor cellularity) were -88% for the 1.2 mg QD group and -85% for all patients, and -94% and -92%, respectively.”

Source: [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857)

| Response | 1.2 mg QD dose (n=12) | All doses (n=36) |
| --- | --- | --- |
| Objective response rate (CR + PR), n (%) | “9 (75%)” | “23 (64%)” |
| Complete response, n (%) | “0 (0%)” | “2 (6%)” |
| Partial response, n (%) | “9 (75%)” | “21 (58%)” |
| Stable disease, n (%) | “3 (25%)” | “12 (33%)” |
| Progressive disease, n (%) | “0 (0%)” | “1 (3%)” |
| Disease control rate, n (%) | “12 (100%)” | “35 (97%)” |

Source: [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857)

<a id="topic-3.1.2.8.3-15"></a>

###### Objective response in the evaluable and intention-to-treat populations

> “The 1.2 mg daily dosing cohort had an ORR of 75% in the evaluable population. Among participants in the intention-to-treat population, the overall response rate was 55% across all doses tested and the response rate was 64% for participants in the 1.2 mg daily dosing cohort.”
> “These data were reported in a poster presentation at ESMO in 2024.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-3.1.2.8.3-16"></a>

###### Interim partial response and tumor volume change at Week 16 and Week 28

> “The best response in the evaluable population as assessed by blinded independent central review (BICR) was partial response (PR) in 6/12 patients (50%) for 1.2 mg QD, 3/13 patients (23.1%) for 4 mg BIW, and 5/11 patients (45.5%) for 2 mg BIW. Disease control rate was 100%, 91%, and 97% in these groups, respectively.”
> “Median volume change (BICR) from baseline was -51.9% for 1.2 mg QD, -9.5% for 4 mg BIW, and -15.2% for 2 mg BIW at Week 16 and -76.4%, -35.5%, and -51.2%, respectively, at Week 28.”

Source: [Gounder et al. (2023b)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.11515)

<a id="topic-3.1.2.8.3-17"></a>

###### Interim partial response and tumor volume change at Week 16 and Week 28, rounded values

> “The best response in the evaluable population by blinded independent central review (BICR) was partial response in 6/12 pts (50%) for 1.2 mg QD, 3/13 pts (23%) for 4 mg BIW, and 5/11 pts (46%) for 2 mg BIW.”
> “Median volume change (BICR) from baseline was -52% for 1.2 mg QD, -10% for 4 mg BIW, and -15% for 2 mg BIW at Week 16 and -76%, -36%, and -52%, respectively, at Week 28, with similar patterns for T2 signal intensity (reduced tumor cellularity).”

Source: [Kasper et al. (2023)](https://doi.org/10.1016/j.annonc.2023.09.1158)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

###### Patient-reported outcomes not analyzed because of limited data and small samples

> “Analysis of patient-reported outcomes was precluded by limited data availability and small sample sizes.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.4-2"></a>

###### Registered open-label extension GODDESS outcome measures

> “OLE: PRO - GODDESS DTSS Total Symptom Score”
> “OLE: PRO - GODDESS DTSS Physical Functioning Domain Score”
> “OLE: PRO - WPI using GODDESS DTSS Item 1”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Treatment-related adverse events: no grade 4 or 5 events and no treatment-related serious adverse events

> “Forty-one (97.6%) participants reported treatment-related adverse events (AEs), of which 9 (21.4%) reported grade 3 AEs and none reported serious AEs. There were no grade 4/5 events.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.5-2"></a>

###### Adverse events during the randomized trial: grade 3, serious, and most common events

> “Most AEs (96.5%) were grade 1 or 2. Grade 3 AEs were reported in 16 (38.1%) participants, and serious AEs were reported in six (14.3%) participants. No grade 4 or 5 AEs were reported. The most common AEs were diarrhea (81.0%), nausea (50.0%), and fatigue (42.9%). Most participants (97.6%) reported treatment-related AEs, of which three in each dose arm (9 of 42, 21.4%) reported treatment-related grade 3 AEs and none reported treatment-related serious AEs.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.5-3"></a>

###### Discontinuation because of adverse events by dose arm

> “The median time to treatment discontinuation because of an AE was 74.5 days for 1.2-mg once daily (four participants) and 55.5 days for 2-mg intermittent dosing (two participants). No participants on the 4-mg intermittent dose discontinued varegacestat because of an AE.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.5-4"></a>

###### Treatment-emergent adverse events during the randomized trial by dose arm

| Treatment-emergent adverse event, No. (%) | 1.2 mg once daily (n = 14) | 2 mg intermittent (n = 14) | 4 mg intermittent (n = 14) | All doses (N = 42) |
| --- | --- | --- | --- | --- |
| Any event | “14 (100.0)” | “14 (100.0)” | “14 (100.0)” | “42 (100.0)” |
| Treatment-related | “14 (100.0)” | “13 (92.9)” | “14 (100.0)” | “41 (97.6)” |
| Grade ≥3 | “5 (35.7)” | “7 (50.0)” | “4 (28.6)” | “16 (38.1)” |
| Treatment-related grade ≥3 | “3 (21.4)” | “3 (21.4)” | “3 (21.4)” | “9 (21.4)” |
| Serious | “1 (7.1)” | “4 (28.6)” | “1 (7.1)” | “6 (14.3)” |
| Leading to dose reduction | “6 (42.9)” | “0” | “5 (35.7)” | “11 (26.2)” |
| Leading to interruption | “11 (78.6)” | “5 (35.7)” | “7 (50.0)” | “23 (54.8)” |
| Leading to study drug withdrawal | “4 (28.6)” | “2 (14.3)” | “0” | “6 (14.3)” |
| Diarrhea | “14 (100.0)” | “8 (57.1)” | “12 (85.7)” | “34 (81.0)” |
| Nausea | “7 (50.0)” | “4 (28.6)” | “10 (71.4)” | “21 (50.0)” |
| Fatigue | “7 (50.0)” | “5 (35.7)” | “6 (42.9)” | “18 (42.9)” |
| Alopecia | “7 (50.0)” | “2 (14.3)” | “4 (28.6)” | “13 (31.0)” |
| Dry skin | “7 (50.0)” | “1 (7.1)” | “5 (35.7)” | “13 (31.0)” |
| Hypophosphatemia | “6 (42.9)” | “5 (35.7)” | “2 (14.3)” | “13 (31.0)” |
| Headache | “1 (7.1)” | “5 (35.7)” | “6 (42.9)” | “12 (28.6)” |
| Stomatitis | “7 (50.0)” | “2 (14.3)” | “3 (21.4)” | “12 (28.6)” |
| Amenorrhea | “4 (28.6)” | “3 (21.4)” | “4 (28.6)” | “11 (26.2)” |
| AST increased | “4 (28.6)” | “4 (28.6)” | “3 (21.4)” | “11 (26.2)” |
| Hot flush | “3 (21.4)” | “4 (28.6)” | “4 (28.6)” | “11 (26.2)” |
| Vomiting | “3 (21.4)” | “4 (28.6)” | “4 (28.6)” | “11 (26.2)” |

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.5-5"></a>

###### Adverse events of special interest: liver enzyme elevations, cutaneous squamous cell carcinoma, and ovarian toxicity

> “Among AEs of special interest (Appendix Table A1, online only), grade ≥2 ALT/AST elevations were reported in four participants (9.5%)—two on the 2-mg intermittent dose and two on the 4-mg intermittent dose—and squamous cell carcinoma of the skin was reported in one participant (2.4%) on the 2-mg intermittent dose. Ovarian toxicity events, a known class effect of GSIs, were reported in 12 of the 23 women of childbearing potential (52.2%), including amenorrhea in four women on the 1.2-mg once-daily dose, three on the 2-mg intermittent dose, and four on the 4-mg intermittent dose, as well as premature menopause in one woman on the 1.2-mg once-daily dose. Among the 12 women who experienced ovarian toxicity, events resolved for six women (50%) and had not resolved at last follow-up for six women (50%).”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.5-6"></a>

###### Adverse events of special interest by dose arm, appendix table

| Event, No. (%) | 1.2 mg once daily (n = 14) | 2 mg intermittent (n = 14) | 4 mg intermittent (n = 14) | All doses (N = 42) |
| --- | --- | --- | --- | --- |
| One or more adverse events of special interest | “6 (42.9)” | “5 (35.7)” | “5 (35.7)” | “16 (38.1)” |
| Amenorrhea | “3 (21.4)” | “3 (21.4)” | “4 (28.6)” | “10 (23.8)” |
| Premature menopause | “0” | “0” | “1 (7.1)” | “1 (2.4)” |
| Elevated liver enzymes (CTCAE grade ≥2) | “2 (14.3)” | “2 (14.3)” | “0” | “4 (9.5)” |
| Squamous cell carcinoma of skin | “1 (7.1)” | “0” | “0” | “1 (2.4)” |

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.5-7"></a>

###### Open-label extension: five additional participants with treatment-related grade 3 adverse events

> “During continued varegacestat exposure at 1.2 mg once daily in the open-label extension, there were no grade 4 AEs, no deaths, no serious treatment-related AEs and five additional participants reported treatment-related grade 3 AEs (total, 14 participants [33.3%]; Appendix Table A3).”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.5-8"></a>

###### Treatment-emergent adverse events in the randomized trial and open-label extension combined

| Treatment-emergent adverse event, No. (%) | Original 1.2 mg once daily (n = 14) | Original 2 mg intermittent (n = 14) | Original 4 mg intermittent (n = 14) | All doses (N = 42) |
| --- | --- | --- | --- | --- |
| Grade ≥3 | “6 (42.9)” | “11 (78.6)” | “6 (42.9)” | “23 (54.8)” |
| Treatment-related grade ≥3 | “4 (28.6)” | “6 (42.9)” | “4 (28.6)” | “14 (33.3)” |
| Serious | “1 (7.1)” | “6 (42.9)” | “1 (7.1)” | “8 (19.0)” |
| Leading to dose reduction | “7 (50.0)” | “3 (21.4)” | “8 (57.1)” | “18 (42.9)” |
| Leading to interruption | “11 (78.6)” | “8 (57.1)” | “9 (64.3)” | “28 (66.7)” |
| Leading to study drug withdrawal | “4 (28.6)” | “4 (28.6)” | “1 (7.1)” | “9 (21.4)” |
| Diarrhea | “14 (100.0)” | “9 (64.3)” | “12 (85.7)” | “35 (83.3)” |
| Nausea | “8 (57.1)” | “5 (35.7)” | “10 (71.4)” | “23 (54.8)” |
| Fatigue | “8 (57.1)” | “6 (42.9)” | “8 (57.1)” | “22 (52.4)” |
| Hypophosphatemia | “7 (50.0)” | “5 (35.7)” | “3 (21.4)” | “15 (35.7)” |
| Stomatitis | “7 (50.0)” | “5 (35.7)” | “3 (21.4)” | “15 (35.7)” |
| Cough | “3 (21.4)” | “5 (35.7)” | “6 (42.9)” | “14 (33.3)” |
| Rash | “1 (7.1)” | “7 (50.0)” | “6 (42.9)” | “14 (33.3)” |
| Upper respiratory tract infection | “3 (21.4)” | “2 (14.3)” | “6 (42.9)” | “11 (26.2)” |

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.5-9"></a>

###### Safety summary and grade 3 or higher adverse events as of January 6, 2025

> “Data cutoff: Jan. 6, 2025”
> “8 pts (19%) had a serious adverse event (AE)”
> “9 pts (21%) discontinued due to an AE”
> “14 (33%) pts had treatment-related Grade 3 AEs”
> “No Grade 4-5 AEs”

Source: [Bui et al. (2025)](https://dtrf.org/wp-content/uploads/2025/12/UNBRANDED_CTOS_2025_RINGSIDE-A_Subgroups_POS_final.pdf)

| Adverse event, n (%) | All grades (N=42) | Grade ≥3 (N=42) |
| --- | --- | --- |
| Diarrhoea | “35 (83.3)” | “5 (11.9)” |
| Nausea | “23 (54.8)” | “0” |
| Fatigue | “22 (52.4)” | “2 (4.8)” |
| Hypophosphatemia | “15 (35.7)” | “0” |
| Stomatitis | “15 (35.7)” | “1 (2.4)” |
| Cough | “14 (33.3)” | “1 (2.4)” |
| Headache | “14 (33.3)” | “0” |
| Rash | “14 (33.3)” | “0” |

Source: [Bui et al. (2025)](https://dtrf.org/wp-content/uploads/2025/12/UNBRANDED_CTOS_2025_RINGSIDE-A_Subgroups_POS_final.pdf)

<a id="topic-3.1.2.8.5-10"></a>

###### Updated safety: grade 3 drug-related TEAEs in 14 of 42 participants

> “The 5 most common Grade 1-2 treatment-emergent adverse events (TEAEs) were diarrhea, nausea, fatigue, headache and dry skin. Grade 3 drug-related TEAEs were reported in 14/42 (33%) pts, the most common being skin-related. There were no Grade 4-5 or serious drug-related TEAEs. No new safety signals were observed during long-term treatment.”

Source: [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857)

<a id="topic-3.1.2.8.5-11"></a>

###### Interim safety: grade 3 drug-related TEAEs in 26.2% of patients

> “Consistent with the mechanism of action of GSIs, the five most common Grade 1-2 treatment-emergent adverse events (TEAEs) were diarrhea, nausea, fatigue, alopecia, and dry skin. Grade 3 drug-related TEAEs were reported in 26.2% of patients across all tested doses. There were no Grade 4, Grade 5, or serious TEAEs related to AL102 per investigator assessment.”

Source: [Gounder et al. (2023b)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.11515)

<a id="topic-3.1.2.8.5-12"></a>

###### Interim safety: grade 3 drug-related TEAE in 10 of 42 patients

> “The 5 most common Grade 1-2 treatment-emergent adverse events (TEAE) were diarrhea, nausea, fatigue, alopecia, and dry skin. Grade 3 drug-related TEAE were reported in 10/42 (24%) pts. There were no Grade 4-5 or serious drug-related TEAE and no new safety signals.”

Source: [Kasper et al. (2023)](https://doi.org/10.1016/j.annonc.2023.09.1158)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

- RINGSIDE Part A was an open-label, randomized, dose-finding phase II study with 14 participants in each of three varegacestat dose regimens and no placebo or active comparator arm; the investigators describe it as having “small sample sizes and no placebo or active comparator arm”. The primary endpoint was safety; change in tumor volume at week 16 by BICR was the secondary endpoint, and RECIST v1.1 objective response rate was exploratory.
- The sample size was powered for the change in tumor volume from baseline within each regimen (12 participants per regimen, 85% power), so comparisons between regimens are descriptive: the LS mean reduction at week 16 was statistically significant for 1.2 mg once daily (–39.8%) and not for the 2 mg (–21.7%) or 4 mg (–17.8%) intermittent regimens. The efficacy analysis set (37 MRI-evaluable participants, 88.1%) excluded participants without measurable disease at baseline or a valid MRI at week 4 or later.
- The open-label extension switched all 29 continuing participants (69.0%) to 1.2 mg once daily between week 36 and week 76, so long-term results by original dose arm (confirmed ORR 57.1%, 50.0%, and 64.3%) reflect both the randomized regimen and later exposure to 1.2 mg once daily. Participants could continue varegacestat after progression by BICR with sponsor approval.
- Response rates differ by data cutoff and analysis population: an evaluable-population ORR of 75% for 1.2 mg once daily and 64% for all doses (April 10, 2024), an intention-to-treat ORR of 55% for all doses in the 10-K, and a confirmed ORR of 57.1% among all 42 participants as of January 6, 2025. Two abstracts with the April 10, 2024 cutoff report different median times on treatment (25.4 and 23.1 months), and two interim abstracts report grade 3 drug-related TEAEs in 26.2% (January 3, 2023 cutoff) and in 10 of 42 participants (24%).
- Subgroup analyses were post hoc, pooled across dose regimens, and limited to subgroups with at least 5 participants; the investigators state that “The sample sizes in each subgroup are relatively small”. The T2-weighted signal and exposure-response analyses were exploratory.
- Patient-reported outcomes were not analyzed because of “limited data availability and small sample sizes”. Ovarian toxicity had not resolved at last follow-up in 6 of 12 affected women. The study was sponsored by Immunome and Ayala Pharmaceuticals.

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725); [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857); [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516); [Gounder et al. (2023b)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.11515); [Kasper et al. (2023)](https://doi.org/10.1016/j.annonc.2023.09.1158); [Bui et al. (2025)](https://dtrf.org/wp-content/uploads/2025/12/UNBRANDED_CTOS_2025_RINGSIDE-A_Subgroups_POS_final.pdf); [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf); [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-3.1.2.9-2"></a>

###### Small sample sizes and no placebo or active comparator arm

> “RINGSIDE phase II was a dose-finding study with random assignment to three dose groups with small sample sizes and no placebo or active comparator arm. Analysis of patient-reported outcomes was precluded by limited data availability and small sample sizes. The ongoing RINGSIDE phase III trial is designed to confirm the clinical activity and safety profile and assess patient-reported outcomes, with once-daily varegacestat in a larger DT population.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.9-3"></a>

###### Limitations of the post hoc subgroup analysis

> “This is a post hoc analysis of outcomes in different patient subgroups”
> “The sample sizes in each subgroup are relatively small”
> “We limited our analysis to subgroups with at least 5 patients”
> “The dosing regimen for patients on 2/4 mg intermittent changed to 1.2 mg once daily when they entered the OLE, per the study design”

Source: [Bui et al. (2025)](https://dtrf.org/wp-content/uploads/2025/12/UNBRANDED_CTOS_2025_RINGSIDE-A_Subgroups_POS_final.pdf)

<a id="heading-3.1.3"></a>

#### 3.1.3 CA002-001

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Primary and secondary objectives

> “The primary objective was to establish the safety, tolerability and Maximum Tolerated Dose (MTD) of BMS-986115.”
> “The secondary objectives were to assess pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of BMS-986115.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.1-2"></a>

###### Registry statement of purpose

> “Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-986115 in Subjects With Advanced Solid Tumors”
> “The primary purpose of this study is to evaluate the safety and effectiveness of daily doses of BMS-986115 in subjects with advanced solid tumors”

Source: [ClinicalTrials.gov NCT01986218](https://clinicaltrials.gov/study/NCT01986218)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Enrollment and completion dates

> “The first patient was enrolled on 11th December 2013 and the study was completed on 29th March 2016. There were no subjects on study at the time of study completion.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.2-2"></a>

###### Registry status, dates, and sites

| Study characteristic | Quoted record |
| --- | --- |
| Protocol number | “CA002-001” |
| Sponsor | “Bristol-Myers Squibb” |
| Overall status | “Terminated” |
| Reason stopped | “(Non-safety reason, business objectives have changed)” |
| Study start | “2013-11” |
| Primary completion | “2016-03” |
| Study completion | “2016-03” |
| United States site | “Usc/Norris Comprehensive Cancer Center” |
| Site cities | “Los Angeles”; “Parkville”; “Vancouver”; “Toronto” |

Source: [ClinicalTrials.gov NCT01986218](https://clinicaltrials.gov/study/NCT01986218)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Open-label, multi-arm phase 1 dose escalation

> “In this open label phase I dose escalation study, BMS-986115 was administered as an oral single agent on once daily continuous (QD) and two times weekly intermittent (BIW) schedules.”
> “The study was an ascending multiple-dose Phase I study and conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice Guidelines.”
> “Arm A and Arm B were conducted in a sequential manner.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.3-2"></a>

###### Accelerated titration followed by a 3 + 3 design

> “The dose escalation phase was initially conducted using an accelerated titration design [18] in which a single subject was enrolled in each cohort, and was switched to a 3 + 3 design with modified Fibonacci dose escalation if any of the following occurred in a single-subject cohort: grade 2 treatment-related diarrhoea lasting >36 h despite appropriate medical management; or any other grade 2 treatment-related adverse advent (AE), excluding asymptomatic electrolyte abnormalities that were manageable with appropriate supplements, alopecia and fatigue lasting ≤5 days.”
> “For single-subject cohorts, dose escalation occurred in increments of 100% above the previous dose.”
> “Dose escalation continued until the MTD was established or until the sponsor and investigators concurred that further dose escalation was not warranted. Once MTD was established in a given study arm, approximately 6 additional subjects were to be treated in a dose expansion cohort, at a dose equal to or below the MTD.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.3-3"></a>

###### Registry design fields

| Study characteristic | Quoted record |
| --- | --- |
| Phase | “Phase 1” |
| Allocation | “Non-Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “None (Open Label)” |
| Primary purpose | “Treatment” |
| Arms | “Arm A: Dose Escalation (BMS-986115)”; “Arm A: Dose Expansion (BMS-986115)”; “Arm B: Dose Escalation (BMS-986115)”; “Arm B: Dose Expansion (BMS-986115)” |

Source: [ClinicalTrials.gov NCT01986218](https://clinicaltrials.gov/study/NCT01986218)

<a id="topic-3.1.3.3-4"></a>

###### Sponsor and funding

> “Funding This study was sponsored and funded by Bristol-Myers Squibb.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.3-5"></a>

###### Sponsor and population as described by Immunome

> “A Phase 1 dose-escalation clinical trial was conducted by Bristol-Myers Squibb, or BMS, in patients with solid tumors.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Advanced solid tumours refractory to or relapsed from standard therapies

> “Male and female subjects who were 18 years or older and had a histological or cytological diagnosis of advanced solid tumours refractory to or relapsed from standard therapies were eligible.”
> “The inclusion criteria included life expectancy of ≥3 months, ECOG performance status 0–1, and adequate organ function including ECG parameters.”
> “Subjects were required to have an adequate lipid profile as increases in triglycerides were seen in the multiple dose rat study with BMS-986115.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.4-2"></a>

###### Main exclusion criteria

> “The main exclusion criteria were: symptomatic or unstable brain metastases, any serious medical disorders including active infection and significant cardiovascular disease, major thromboembolic events or bleeding diathesis within 6 months of study entry, current or recent GI disease that increases the risk of diarrhoea, any major surgery or GI disorder that would interfere with administration of oral medications, conditions requiring chronic systemic glucocorticoid use, therapeutic anticoagulation, and concomitant second malignancies (except adequately treated in situ cancers and non-melanomatous skin cancers).”
> “Prior exposure to BMS-986115 or other Notch inhibitors was not allowed and those with a history of allergy to Notch inhibitors including BMS-986115related compounds were excluded.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.4-3"></a>

###### Washout and prohibited concomitant medications

> “Patients required a washout period of at least 6 months for prior therapy with nucleoside analogues, 6 weeks for prior therapy with nitrosoureas, mitomycin C and liposomal doxorubicin and 4 weeks for other anticancer therapies.”
> “The prohibited concomitant medications included herbal supplements, medications causing Torsades de Pointes, strong inhibitors or inducers of CYP3A4 or P-gp, and sensitive substrates of CYP3A4 with a narrow therapeutic window.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.4-4"></a>

###### Registry criteria for gastrointestinal disease and hypertriglyceridemia

> “Current or recent (within 3 months of study drug administration) gastrointestinal disease such as chronic or intermittent diarrhea, or disorders that increase the risk of diarrhea, such as inflammatory bowel disease.”
> “Uncontrolled (≥ Grade 2) hypertriglyceridemia (fasting triglycerides > 300 mg/dL (3.42 mmol/L))”

Source: [ClinicalTrials.gov NCT01986218](https://clinicaltrials.gov/study/NCT01986218)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Dose levels in the once-daily and twice-weekly arms

> “BMS-986115 was administered orally once daily (QD) at doses of 0.3, 0.6, 1.2, 1.5, and 2 mg (Arm A) or twice weekly (BIW) on consecutive days at doses of 2, 4, 8 mg (Arm B).”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.5-2"></a>

###### Cycle structure and dosing days

> “In the treatment period, the first cycle was 7 days in duration, and all subsequent cycles were 28 days in duration. Subjects received a single dose of BMS-986115 on Cycle 1 Day 1. In Cycle 2 and all subsequent cycles, subjects in Arm A received QD doses of BMS-986115 (i.e., Day 1 to Day 28 inclusive) and subjects in Arm B received BIW doses of BMS-986115 (i.e., Days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle).”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.5-3"></a>

###### Dose interruption, dose reduction, and treatment duration

> “Dose interruption (up to 28 days) and/or dose modification (up to 2 dose reductions) were permitted in the event of study drug toxicity. Subjects could continue to receive treatment in the study until they experienced disease progression, unacceptable AEs, or withdrew consent.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.5-4"></a>

###### Capsule formulation

> “BMS-986115 was supplied as grey hard gelatin capsules, including a size 1 capsule containing 0.3 mg BMS-986115 and a size 0 capsule containing 2 mg BMS-986115.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.5-5"></a>

###### Registry arm descriptions

> “Continuous daily dosing until disease progression or unacceptable toxicity”
> “Twice weekly dosing until disease progression or unacceptable toxicity”

Source: [ClinicalTrials.gov NCT01986218](https://clinicaltrials.gov/study/NCT01986218)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Maximum Tolerated Dose as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Gastrointestinal toxicity as the dose-limiting effect of Notch inhibition

> “In animal studies, the main pharmacological toxicities included dose-dependent gastrointestinal (GI) toxicity, lymphoid depletion, and interruption of ovarian follicle maturation.”
> “As prolonged inhibition of the Notch pathway is associated with increased GI toxicity, an oral Notch inhibitor with a short half-life that allows transient rather than continuous target engagement is desirable.”
> “The clinical development of Notch inhibitors has been hampered by on-target GI toxicity and most drugs have not been tolerable at daily continuous schedule [19–21].”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.6.1-2"></a>

###### Dose-limiting toxicity period and definition

> “DLT period was 35 days (from C1, duration of which was 7 days, to end of cycle 2, duration of which was 28 days).”
> “Gr ≥3 diarrhoea lasting >24 h despite appropriate medical management; any other drug-related Gr ≥3 non-hematologic AE, except hyperlipidemia in subjects not receiving maximum medical management or electrolyte abnormalities that may be managed with supplements.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.6.1-3"></a>

###### Estimation of the maximum tolerated dose

> “The estimation of the MTD was based on the probability of DLT in cycle 1 and 2 for patients in dose escalation.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.6.1-4"></a>

###### Registry primary outcome: safety and tolerability

> “Safety and tolerability of multiple daily doses of BMS-986115”
> “Measured by the frequency of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, Grade 3 or 4 AEs, deaths, laboratory abnormalities and clinically relevant electrocardiogram (ECG) changes from baseline”

Source: [ClinicalTrials.gov NCT01986218](https://clinicaltrials.gov/study/NCT01986218)

<a id="topic-3.1.3.6.1-5"></a>

###### Safety assessments

> “Safety assessments consisted of physical examination, vital signs, weight, performance status assessment using ECOG (Eastern Cooperative Oncology Group) criteria and documentation of AEs and serious AEs (SAEs) for all treated subjects using the National Cancer Institute’s Common Toxicity Criteria for Adverse Events v4.03.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.6.1-6"></a>

###### Secondary endpoint: pharmacokinetics of BMS-986115 and BMT-100948

> “Pre and post treatment EDTA peripheral whole blood samples for the PK determination of BMS-986115 and its equally active metabolite BMT-100948 were collected on days 1 (pre-dose and 0.5, 1, 1.5, 2, 4, and 8 h post-dose), 2 (24 h post first dose), 3 (48 h post first dose), 4 (72 h post first dose) and 5 (120 h post first dose) of cycle 1 for both Arm A and Arm B”
> “Plasma concentrations of BMS-986115 and BMT-100948 were determined using a validated liquid chromatography-tandem mass spectrometry assay.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.6.1-7"></a>

###### Secondary endpoint: Notch pathway gene expression as a pharmacodynamic biomarker

> “Expression of Notch pathway-related genes in peripheral blood was measured as surrogate PD biomarkers for BMS-986115.”
> “The level of inhibition of Hes1 and Deltex1 expression by oral doses of BMS-986115 in peripheral blood was measured as surrogate PD biomarkers.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.6.1-8"></a>

###### Secondary endpoint: preliminary anti-tumour activity by RECIST 1.1

> “Tumour assessments by CT or MRI were performed at baseline and approximately every 8 weeks during treatment, and at the end of treatment or 30-day follow-up if not done within the preceding 8 weeks. The radiological response to therapy was assessed using Response Evaluation Criteria in Solid Tumor (RECIST) 1.1.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.6.1-9"></a>

###### Registry secondary outcome: investigator-assessed tumor response

> “Preliminary anti-tumor activity of BMS-986115 as measured by response evaluation criteria in solid tumors (RECIST)”
> “Tumor Response based on the Investigator's assessment using RECIST v1.1 [categorized as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD)]”

Source: [ClinicalTrials.gov NCT01986218](https://clinicaltrials.gov/study/NCT01986218)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned participants per arm

> “Approximately 20 subjects were planned per study arm, including dose escalation and expansion, with 1 to 6 subjects treated per dose level and at least 12 subjects treated at the MTD.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.7.1-2"></a>

###### Participants treated and evaluable for dose-limiting toxicity

> “A total of 36 patients were treated in the study (24 in Arm A and 12 in Arm B).”
> “Of 24 patients treated in Arm A, 20 patients were DLT evaluable for 5 QD dose levels evaluated (0.3 mg [N = 2], 0.6 mg [N = 2], 1.2 mg [N = 5], 1.5 mg [N = 6], and 2 mg [N = 5]) (Table 2).”
> “Of 12 patients treated within Arm B, 10 were DLT evaluable for 3 BIW dose levels (2 mg [N = 2], 4 mg [N = 2], and 8 mg [N = 6]).”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.7.1-3"></a>

###### Participants treated per dose level

| Dose level | Total no. of patients | No. of DLT evaluable patients |
| --- | --- | --- |
| Arm A, 0.3 mg once daily | “2” | “2” |
| Arm A, 0.6 mg once daily | “2” | “2” |
| Arm A, 1.2 mg once daily | “6” | “5” |
| Arm A, 1.5 mg once daily | “7” | “6” |
| Arm A, 2.0 mg once daily | “7” | “5” |
| Arm B, 2 mg twice weekly | “2” | “2” |
| Arm B, 4 mg twice weekly | “2” | “2” |
| Arm B, 8 mg twice weekly | “8” | “6” |

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Safety and pharmacokinetic populations

> “All subjects who received at least one dose of BMS-986115 were evaluated for safety parameters.”
> “Plasma concentration-time data for BMS-986115 and an equally active metabolite BMT-100948 were reported for subjects who received at least one dose of study medication. Non-compartmental analysis (NCA) was performed to characterize the PK parameters for the parent compound (BMS-986115) using nominal time.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.7.2-2"></a>

###### Descriptive statistical analysis

> “Demographics, baseline characteristics, safety and efficacy measurements were described using descriptive statistics. For PD analysis, geometric mean relative gene expression data for the Notch pathway genes Deltex1 and Hes1 were plotted.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.7.2-3"></a>

###### Inclusion of CA002-001 participants in a pooled exposure-response safety analysis

> “Safety analysis included 157 participants treated with VAR:”
> “36 from Ph1 Study CA002001 (solid tumors).”

Source: [Fetterly et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_4_ESMO-2026_VAR-ER_Poster_Final.pdf)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Treatment until progression and discontinuation for adverse events

> “Sixteen (67%) of the 24 subjects treated in Arm A and 6 (50%) of the 12 subjects treated in Arm B continued to receive treatment until disease progression. A total of 9 subjects discontinued treatment after experiencing one or more AEs that were either related to study drug (N = 5, 3 subjects in Arm A and 2 in Arm B) or not related to the study drug (N = 4, 2 subjects in each arm).”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.8.1-2"></a>

###### Duration of treatment

> “The median duration of time on treatment was 5.6 weeks (range 0.9–57.9 weeks) for the overall study population, and was similar for subjects in Arm A (median 5.8 weeks, range 1.7–57.9 weeks) and those in Arm B (median 5.5 weeks, range 0.9–48.4 weeks).”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.8.1-3"></a>

###### Early termination

> “The MTD was not established for BIW dosing schedule, as the study was terminated prior to this being formally established.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Demographics, performance status, cancer types, and prior therapy (N = 36)

| Characteristic | N (%) |
| --- | --- |
| Male | “17 (47)” |
| Female | “19 (53)” |
| Age, mean (SD), years | “58 (14)” |
| Age, range | “23–84” |
| White | “29 (81)” |
| Asian | “7 (19)” |
| Baseline WHO performance status 0 | “10 (28)” |
| Baseline WHO performance status 1 | “25 (69)” |
| Baseline WHO performance status 2 | “1 (3)” |
| Colon cancer | “5 (14)” |
| Adenoid cystic carcinoma | “5 (14)” |
| Cholangiocarcinoma | “3 (8)” |
| Desmoid fibromatosis | “1 (3)” |
| Other cancer types | “8 (22)” |
| Prior surgery | “36 (100)” |
| Prior radiotherapy | “22 (61)” |
| Prior systemic therapy for metastatic disease | “29 (81)” |
| Four or more prior systemic treatments | “9 (25)” |

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.8.2-2"></a>

###### One participant with desmoid fibromatosis

> “In this trial, one patient with desmoid fibromatosis was enrolled.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Best tumour response and stable disease for more than 6 months

> “Of the 36 treated subjects, 21 (58%) subjects had progressive disease and 11 (31%) had stable disease (SD) as a best tumour response and 4 were not evaluable. Of the 11 subjects with SD, 5 (1 clear cell renal cell carcinoma, 1 fibromatosis, 2 adenoid cystic carcinoma, and 1 retroperitoneal liposarcoma) had SD for more than 6 months (Supplementary Figure 1).”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.8.3-2"></a>

###### Participant with fibromatosis treated at 1.5 mg once daily

> “In addition, the patient with fibromatosis, who did not have documented disease progression before study entry, achieved SD with maximum disease shrinkage of 16.5% after ~9 months of treatment.”
> “All 3 patients who had prolonged SD with disease shrinkage were treated with the pharmacodynamically active doses of BMS-986115 (1.2 mg QD [renal cell carcinoma case], 1.5 mg QD [fibromatosis case], and 2 mg QD [retroperitoneal liposarcoma case]).”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.8.3-3"></a>

###### Participant with desmoid fibromatosis as described by Immunome

> “This patient demonstrated tumor shrinkage of 16.5% while on study.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-3.1.3.8.3-4"></a>

###### Pharmacokinetics: absorption, half-life, and accumulation

> “BMS-986115 was rapidly absorbed following single/multiple-dose administration over the 0.3-mg to 8-mg dose range, and the median Tmax was within a range of 1 h to 3 h. There was a dose-related increase for both Cmax and AUCtau after BMS-986115 administration following single/multiple-dose administration over the 0.3-mg to 8-mg dose range. Following multiple once daily dose administration of BMS-986115, the median half-life ranged from 17.24 h to 28.01 h.”
> “The median accumulation ratios (AUCtau ratio of Day 15/Day 1 values) of BMS-986115 after once daily dosing were 2.64, 3.9, 3.66, 2.33, and 2.19 for 0.3-, 0.6-, 1.2-, 1.5-, and 2-mg doses, respectively. Accumulation ratios (AUCtau ratio of Day 16/Day 1) of BMS-986115 after two consecutive days dosing in a week (Arm B) were 2.47, 3.01, and 2.77 for 2-, 4- and 8-mg doses, respectively.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.8.3-5"></a>

###### Pharmacokinetics: active metabolite BMT-100948

> “Plasma concentrations of BMT-100948 were low relative to plasma concentrations of the parent drug (BMS-986115). Median Cmax% ratios for BMT-100948 to that of BMS-986115 after a single dose on Day 1 ranged from 5 to 13%, and after multiple doses on Day 15 ranged from 12 to 16%, respectively. Similarly, median AUCtau ratio for BMT-100948 to that of BMS-986115 after a single dose on Day 1 ranged from 14% - 22%, and after multiple doses on Day 15 ranged from 17% - 27%, respectively.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.8.3-6"></a>

###### Pharmacodynamics: inhibition of Hes1 and Deltex1 expression

> “After 2 weeks of dosing at the highest tolerated doses of 1.2 mg QD and 1.5 mg QD, geometric mean relative expression of Hes1 was continuously inhibited by >50% below baseline, with peak inhibition of >80% (Fig. 2). Similarly, geometric mean relative expression of Deltex1 was continuously inhibited by greater than 45% for the entire dosing interval, with peak inhibition of >60% (Fig. 2). At the highest tolerated dose level of 4 mg BIW, geometric mean relative expression of Hes1 was inhibited by >75% for at least 48 h of the weekly dosing cycle and Deltex1 was inhibited by greater than 50%.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Maximum tolerated dose and dose-limiting toxicities in the once-daily arm

> “Based on the incidence of DLT, the MTD for QD dosing of BMS-986115 was 1.5 mg QD. At this dose level, 1 DLT (Gr 3 nausea) was observed in one of 6 patients treated. No DLT was observed in 5 evaluable patients treated at 1.2 mg QD. The 2 mg QD dose was not tolerated with DLTs in 3 of the 5 DLT-evaluable patients (Gr 3 ileus; Gr 3 nausea; Gr 3 pruritus/urticaria).”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.8.5-2"></a>

###### Dose-limiting toxicities in the twice-weekly arm

> “None of the two patients treated at 4 mg BIW had DLT. But, a higher dose of 8 mg BIW was not tolerated with DLTs in 2 of the 6 DLT-evaluable subjects (Gr 3 diarrhoea; Gr 3 nausea/dehydration/anorexia with Gr 2 fatigue).”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.8.5-3"></a>

###### Adverse events of any causality and treatment-related adverse events

> “There were no treatment-related deaths. Adverse events (AE) were reported in all 36 (100%) subjects. The most frequently reported AEs (>50% of all treated subjects) regardless of causality were diarrhoea (72%), nausea (69%), hypophosphataemia (67%), fatigue (64%), decreased appetite (58%), and vomiting (53%).”
> “In the QD arm, a dose related trend was apparent in the frequency of GI events but this trend was not observed in the BIW arm (Table 3). The most common treatment-related Gr 3 or 4 AEs were hypophosphataemia (39%), diarrhoea (19%), nausea (11%), hypokalaemia (11%) and hyponatraemia (6%) (Table 4).”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.8.5-4"></a>

###### Treatment-related adverse events of all grades by dose level

| Adverse event | 1.2 mg once daily (N = 6) | 1.5 mg once daily (N = 7) | Arm A total (N = 24) | All patients (N = 36) |
| --- | --- | --- | --- | --- |
| Diarrhoea | “6 (100)” | “6 (86)” | “18 (75)” | “26 (72)” |
| Nausea | “4 (67)” | “5 (71)” | “15 (63)” | “22 (61)” |
| Vomiting | “2 (33)” | “4 (57)” | “12 (50)” | “16 (44)” |
| Hypophosphataemia | “6 (100)” | “4 (57)” | “16 (67)” | “23 (64)” |
| Decreased appetite | “2 (33)” | “1 (14)” | “8 (33)” | “13 (36)” |
| Hypokalaemia | “3 (50)” | “2 (29)” | “7 (29)” | “10 (28)” |
| Rash | “3 (50)” | “2 (29)” | “8 (33)” | “11 (31)” |
| Pruritus | “0” | “2 (29)” | “6 (25)” | “9 (25)” |
| Fatigue | “2 (33)” | “4 (57)” | “10 (42)” | “16 (44)” |

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.8.5-5"></a>

###### Serious adverse events

> “Overall, SAEs were reported for 18 (50%) subjects. Eight (6 in Arm A and 2 in Arm B) (22%) experienced SAEs that were treatment-related: Gr 3 diarrhoea (Arm B), Grade 3 diarrhoea with Gr 2 abdominal pain (Arm A), Gr 2 diarrhoea with Gr 2 dehydration (Arm A), Gr 3 nausea, dehydration and decreased appetite (Arm B), Gr 3 nausea with Gr 3 fatigue and Gr 4 hypophosphataemia (Arm A), Gr 3 colitis (Arm A), Gr 2 anaemia and Gr 3 pulmonary embolism (Arm A), and Gr 3 ileus (Arm A).”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.8.5-6"></a>

###### Discontinuation due to adverse events

> “Nine subjects (25%) discontinued treatment due to AEs (Table 2), including 5 subjects who discontinued due to treatment-related diarrhoea with or without nausea (N = 3), dermatitis acneiform (N = 1), or dehydration and anorexia (N = 1). Four other subjects discontinued treatment due to non-treatment related AEs.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.8.5-7"></a>

###### Grade 3 or 4 diarrhoea at the maximum tolerated dose

> “Although Gr 3/4 diarrhoea related to the study treatment was observed in 2 of 7 patients (29%) treated at this dose level, these events resolved to Gr 1 within 24 h with appropriate medical management.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

- CA002-001 was an open-label, nonrandomized phase 1 dose-escalation study without a comparator arm in 36 participants with advanced solid tumours (24 in the once-daily arm and 12 in the twice-weekly arm). One participant (3%) had desmoid fibromatosis, so the study provides no estimate of efficacy in desmoid tumors; that participant “did not have documented disease progression before study entry” and was treated at 1.5 mg once daily, a dose above the 1.2 mg once-daily dose used in RINGSIDE.
- Six participants received 1.2 mg once daily, and five of them were evaluable for dose-limiting toxicity. The median duration of treatment was 5.6 weeks (range 0.9 to 57.9 weeks), which limits the assessment of adverse events that emerge with longer exposure.
- The study was “terminated early for business reasons”, and the maximum tolerated dose of the twice-weekly schedule was not established. The registry lists the reason as a “Non-safety reason, business objectives have changed” and shows no posted results.
- Tumour response was assessed by the investigator per RECIST 1.1, with no central review reported. All analyses were descriptive.
- The eligibility criteria required ECOG performance status 0 to 1, and the baseline characteristics report one participant (3%) with baseline WHO performance status 2.
- Bristol-Myers Squibb sponsored and funded the study, and six authors were Bristol-Myers Squibb employees and stockholders.

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/); [ClinicalTrials.gov NCT01986218](https://clinicaltrials.gov/study/NCT01986218); [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.3.9-2"></a>

###### Early termination limits conclusions

> “Despite the demonstration of safety and tolerability, our study was terminated early for business reasons making it difficult to ultimately draw any firm conclusion.”
> “It is regrettable, however, that we did not manage to perform correlative analyses on tumors to identify potential biomarkers of response in these patients because of early termination of the study.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-3.1.3.9-3"></a>

###### Authors employed by the sponsor

> “Conflict of interest Gaurav Bajaj, Bing He, Tian Chen, Lili Zhu, Zhenhao Qi, and Bruce S. Fischer are employees and stockholders of Bristol-Myers Squibb.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="heading-3.1.4"></a>

#### 3.1.4 AL102-501

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Effect of itraconazole on varegacestat pharmacokinetics in healthy participants

> “A Phase 1, Open-Label, Fixed Sequence, 1-way Crossover Study Examining the Effect of Itraconazole on the Pharmacokinetics, Safety and Tolerability After Varegacestat Single Dose Administration to Healthy Participants”
> “Effect of itraconazole on the PK of varegacestat in healthy participants.”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Registry status, dates, and site

| Study characteristic | Quoted record |
| --- | --- |
| Protocol number | “AL102-501” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Completed” |
| Study start (actual) | “2024-11-11” |
| Primary completion (actual) | “2024-12-30” |
| Study completion (actual) | “2025-05-07” |
| First posted | “2024-11-07” |
| Last update posted | “2025-05-11” |
| Site | “Celerion”; “Tempe” |

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Open-label, fixed-sequence, two-period drug-drug interaction study

> “This is an open label, fixed sequence, 1-way crossover drug-drug interaction (DDI) study in healthy participants.”
> “This is a 2-period study. In period 1 a single dose of varegacestat will be administered with PK evaluated predose and up to 192 hours postdose. There will be a 14 -day washout between period 1 and period 2.”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="topic-3.1.4.3-2"></a>

###### Registry design fields

| Study characteristic | Quoted record |
| --- | --- |
| Phase | “Phase 1” |
| Intervention model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Primary purpose | “Other” |
| Keywords | “Drug-Drug Interaction”; “Pharmacokinetics” |

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Healthy adults aged 18 to 55 years

> “Healthy, adult, male or female (of non-childbearing potential only), 18 to 55 years of age, inclusive, at the screening visit.”
> “Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, vital signs, and ECGs, as deemed by the PI or designee”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="topic-3.1.4.4-2"></a>

###### Exclusion criteria

> “History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.”
> “History of any illness that, in the opinion of the PI or designee might confound the results of the study or poses an additional risk to the participant by their participation in the study.”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Single varegacestat dose alone and with itraconazole 200 mg

> “Period 1: varegacestat administration for PK followed by Period 2: itraconazole and varegacestat administration for PK and DDI”
> “Itraconazole (200 mg)”
> “In period 2, itraconzole will be administered once daily for 18 consecutive days. Beginning on Day 4 of Period 2 a single dose of varegacestat will be administered 30 minutes after itraconazole dosing.”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Pharmacokinetic Parameters as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Primary endpoints: varegacestat AUC, Cmax, and Tmax with and without itraconazole

> “AUC0-t for varegacestat administered with and without itraconazole.”
> “AUC0-inf for varegacestat administered with and without itraconazole.”
> “Cmax for varegacestat administered with and without itraconazole.”
> “Tmax for varegacestat administered with and without itraconazole.”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="topic-3.1.4.6.1-2"></a>

###### Pharmacokinetic sampling for varegacestat and its metabolite

> “Blood samples for PK will be collected prior to varegacestat dosing and up to 744 hours post varegacestat dosing for varegacestat and its metabolite.”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="topic-3.1.4.6.1-3"></a>

###### Secondary endpoints: safety, tolerability, and itraconazole trough concentrations

> “Number of subjects who experience treatment-emergent adverse events (TEAEs)”
> “Number of subjects who experience 12-lead ECG abnormalities”
> “Ctrough of itraconazole and hydroxy-itraconazole in combination with varegacestat in healthy participants.”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="topic-3.1.4.6.1-4"></a>

###### Strong CYP3A4 inhibitors prohibited in the first-in-human study

> “The prohibited concomitant medications included herbal supplements, medications causing Torsades de Pointes, strong inhibitors or inducers of CYP3A4 or P-gp, and sensitive substrates of CYP3A4 with a narrow therapeutic window.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Actual enrollment

| Study characteristic | Quoted record |
| --- | --- |
| Enrollment (actual) | “22” |

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

No evidence found.

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

- AL102-501 is known only from its registry record. The record lists the study as “Completed”, with primary completion on 2024-12-30, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so the effect of itraconazole on varegacestat exposure is unknown from public sources.
- The study is an open-label, single-group, fixed-sequence design in 22 healthy participants aged 18 to 55 years, with women limited to those of non-childbearing potential. Each participant received a single dose of varegacestat alone and then with itraconazole, so the results apply to single-dose exposure in healthy adults.
- The registry record does not state the varegacestat dose given.

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="heading-3.1.5"></a>

#### 3.1.5 AL102-502

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Effect of a single varegacestat dose on cardiac repolarization

> “A Phase 1, Randomized, Single-Dose, Positive- and Placebo-Controlled, 3-Way Crossover Study to Evaluate the Effects of Varegacestat on Cardiac Repolarization in Healthy Participants”
> “This clinical study is designed to study the effect of a single dose of varegacestat on cardiac repolarization in healthy adult participants.”

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Registry status, dates, and site

| Study characteristic | Quoted record |
| --- | --- |
| Protocol number | “AL102-502” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Completed” |
| Study start (actual) | “2025-02-24” |
| Primary completion (actual) | “2025-04-08” |
| Study completion (actual) | “2025-05-06” |
| First posted | “2025-03-03” |
| Last update posted | “2025-09-24” |
| Site | “Celerion”; “Tempe” |

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Randomized, placebo- and moxifloxacin-controlled, three-way crossover

> “This is a double-blind (with respect to varegacestat and placebo only), single-dose, randomized, placebo- and positive- controlled, 3-way crossover study.”
> “In each period, cardiodynamic ECGs will be collected predose and for 24 hours postdose.”
> “There will be a washout of at least 14 days between doses. Safety will be monitored throughout the study by repeated clinical and laboratory evaluations.”

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="topic-3.1.5.3-2"></a>

###### Registry design fields

| Study characteristic | Quoted record |
| --- | --- |
| Phase | “Phase 1” |
| Allocation | “Randomized” |
| Intervention model | “Crossover Assignment” |
| Masking | “This is a double-blind study (with respect to varegacestat and placebo only; moxifloxacin will be open label).” |
| Primary purpose | “Other” |
| Keyword | “thorough-QT” |

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Healthy adults aged 18 to 55 years

> “Healthy, adult, male or female (of non childbearing potential), 18 to 55 years of age, inclusive, at the screening visit.”
> “Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, and vital signs, as deemed by the PI or designee”

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="topic-3.1.5.4-2"></a>

###### Exclusion criteria

> “History of any illness that, in the opinion of the PI or designee, might confound the results of the study or pose an additional risk to the participant by their participation in the study.”
> “Have taken an investigational drug or participated in a clinical trial evaluating an investigational drug or device within 30 days (or 5 half-lives) prior to the study drug dose, whichever is longer.”

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Single doses of varegacestat, placebo, and moxifloxacin 400 mg

> “On Day 1 of each period, participants will receive one of 3 treatments: a single dose of varegacestat (Treatment A), a single dose of varegacestat matching placebo (Treatment B), or a single dose of moxifloxacin (Treatment C).”
> “Single oral dose of varegacestat”
> “Moxifloxacin 400 mg”

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Placebo-corrected QTc Change as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Primary endpoint: placebo-corrected QTc change and plasma concentrations

> “Placebo-corrected change from baseline QTc and varegacestat and its metabolite, AL102 MTB, plasma concentrations”
> “PK samples will be collected predose and up to 168 hours post-dose for assessments of varegacestat and AL102 MTB, and up to 24 hours post-dose for assessment of moxifloxacin.”

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="topic-3.1.5.6.1-2"></a>

###### Delayed cardiac repolarization and torsade de pointes

> “The QT interval represents the duration of ventricular depolarization and subsequent repolarization, and is measured from the beginning of the QRS complex to the end of the T wave.”
> “A delay in cardiac repolarization creates an electrophysiological environment that favors the development of cardiac arrhythmias, most clearly torsade de pointes (TdP), but possibly other ventricular tachyarrhythmias as well.”

Source: [FDA guidance, E14 clinical evaluation of QT/QTc interval prolongation (2005)](https://www.fda.gov/media/71372/download)

<a id="topic-3.1.5.6.1-3"></a>

###### Purpose of a thorough QT/QTc study and the threshold of regulatory concern

> “The “thorough QT/QTc study” is intended to determine whether the drug has a threshold pharmacologic effect on cardiac repolarization, as detected by QT/QTc prolongation.”
> “The threshold level of regulatory concern, discussed further below, is around 5 ms as evidenced by an upper bound of the 95% confidence interval around the mean effect on QTc of 10 ms.”
> “Based on similar considerations, a negative “thorough QT/QTc study” is one in which the upper bound of the 95% one-sided confidence interval for the largest time-matched mean effect of the drug on the QTc interval excludes 10 ms.”

Source: [FDA guidance, E14 clinical evaluation of QT/QTc interval prolongation (2005)](https://www.fda.gov/media/71372/download)

<a id="topic-3.1.5.6.1-4"></a>

###### Positive control to establish assay sensitivity

> “The confidence in the ability of the study to detect QT/QTc prolongation can be greatly enhanced by the use of a concurrent positive control group (pharmacological or nonpharmacological) to establish assay sensitivity.”

Source: [FDA guidance, E14 clinical evaluation of QT/QTc interval prolongation (2005)](https://www.fda.gov/media/71372/download)

<a id="topic-3.1.5.6.1-5"></a>

###### Secondary endpoints: ECG parameters, pharmacokinetics, safety, and assay sensitivity

> “Change from baseline, placebo-corrected, and categorical outliers of the ECG parameter QTcF from a single oral dose of varegacestat.”
> “Change from baseline, placebo-corrected, and categorical outliers of the ECG parameter HR from a single oral dose of varegacestat.”
> “Safety and tolerability of a single oral dose of varegacestat by incidences of treatment-emergent adverse events.”
> “Assay sensitivity of the study to detect a small QTc effect using moxifloxacin as a positive control.”

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Actual enrollment

| Study characteristic | Quoted record |
| --- | --- |
| Enrollment (actual) | “32” |

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

No evidence found.

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

- AL102-502 is known only from its registry record. The record lists the study as “Completed”, with primary completion on 2025-04-08, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so the effect of varegacestat on the QTc interval is unknown from public sources.
- The study gave a single oral dose of varegacestat to 32 healthy participants aged 18 to 55 years, with women limited to those of non-childbearing potential. The registry record does not state the dose. In the phase 1 study of BMS-986115, the median accumulation ratio after once-daily dosing at 1.2 mg was 3.66, so exposure after a single dose is lower than exposure after 15 days of once-daily dosing.
- Moxifloxacin, the positive control, was given open label, and blinding applied to varegacestat and placebo only.

Source: [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264); [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="heading-3.1.6"></a>

#### 3.1.6 AL102-503

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Pharmacokinetics, safety, and tolerability in hepatic impairment

> “A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Varegacestat in Participants With or Without Hepatic Impairment”
> “This clinical trial is designed to determine the pharmacokinetics, safety and tolerability of varegacestat in people with impaired liver function compared to people with normal liver function.”

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Registry status, dates, and sites

| Study characteristic | Quoted record |
| --- | --- |
| Protocol number | “AL102-503” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Completed” |
| Study start (actual) | “2025-03-07” |
| Primary completion (actual) | “2025-11-05” |
| Study completion (actual) | “2026-03-06” |
| First posted | “2025-02-24” |
| Last update posted | “2026-03-10” |
| Sites | “Orlando Clinical Research Center”; “The Texas Liver Institute” |

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Open-label, single-dose, parallel-group design with matched controls

> “This is an open-label, single-dose, parallel study to evaluate the effects of varying degrees of impaired hepatic function on the PK, safety, and tolerability of varegacestat in adult participants.”
> “The study will enroll participants with mild (Group 2) and moderate (Group 3) hepatic impairment (HI) and healthy participants with normal hepatic function (Group 1) at a 1:1 ratio.”
> “Healthy participants (Group 1) will be matched by age (± 10 years), body mass index (BMI, ± 15%), and sex to participants with mild to moderate hepatic impairment (Groups 2 and 3).”

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="topic-3.1.6.3-2"></a>

###### Conditional enrollment of participants with severe hepatic impairment

> “Subsequently, if appropriate, the study will enroll participants with severe (Group 4) HI and healthy participants with normal hepatic function (Group 1), as needed, to provide 1:1 matches for Group 4. The decision to conduct Group 4 enrollment will be contingent upon the assessment of the feasibility, PK, and safety data from Groups 1-3.”

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="topic-3.1.6.3-3"></a>

###### Registry design fields

| Study characteristic | Quoted record |
| --- | --- |
| Phase | “Phase 1” |
| Intervention model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Primary purpose | “Other” |

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Hepatic impairment by Child-Pugh category

> “Considered to have HI (of any etiology) that has been clinically stable (no acute episodes of illness due to deterioration in hepatic function) for at least 1 month prior to dosing per the PI and Sponsor and is likely to remain stable throughout the study.”
> “Has a score on the Child-Pugh scale at screening visit and confirmed at check-in as follows:”
> “Mild: ≥5 and ≤6 [Category A]; or”
> “Moderate: ≥7 and ≤9 [Category B]; or”
> “Severe: ≥10 and ≤15 [Category C].”

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="topic-3.1.6.4-2"></a>

###### Healthy matched participants aged 18 to 84 years

> “Healthy, adult, male or female (of nonchildbearing potential only), 18 to 84 years of age, inclusive, at the screening visit. Participant will be matched by age (± 10 years) and sex to a participant with hepatic impairment (HI).”

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Single oral dose of varegacestat on day 1

> “Single oral dose of varegacestat administered on study day 1”

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Pharmacokinetic Parameters as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

###### Primary endpoints: AUC and Cmax of varegacestat and metabolite

> “PK of varegacestat and metabolite from a single oral dose of varegacestat in hepatic impaired adult participants to matched healthy adult participants.”
> “AUC0-t varegacestat and metabolite”
> “AUC0-inf for varegacestat and metabolite”
> “Cmax for varegacestat and metabolite”

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="topic-3.1.6.6.1-2"></a>

###### Secondary endpoints: safety and tolerability

> “Number of subjects who experience treatment emergent adverse events (TEAEs)”
> “Number of subjects who experience abnormalities in vital signs and in clinical laboratory tests such as serum chemistry and hematology”

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Actual enrollment

| Study characteristic | Quoted record |
| --- | --- |
| Enrollment (actual) | “35” |

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

No evidence found.

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

- AL102-503 is known only from its registry record. The record lists the study as “Completed”, with study completion on 2026-03-06, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so varegacestat exposure in hepatic impairment is unknown from public sources.
- The registry gives the actual enrollment as 35 participants but not their distribution across the healthy, mild, moderate, and severe hepatic impairment groups. Enrollment of the severe group (Child-Pugh C) was planned only “if appropriate”, contingent on data from the first three groups.
- The design is open label with a single oral dose, and the registry record does not state the dose.

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="heading-3.1.7"></a>

#### 3.1.7 AL102-504

<a id="heading-3.1.7.1"></a>

##### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

###### Absorption, metabolism, excretion, and mass balance of carbon-14-labeled varegacestat

> “A Phase 1, Open-Label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]Varegacestat Following a Single Oral Dose in Healthy Adult Male Participants”
> “This clinical study is designed to study the mass balance of a single dose of varegacestat in healthy male participants.”

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="heading-3.1.7.2"></a>

##### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

###### Registry status, dates, and site

| Study characteristic | Quoted record |
| --- | --- |
| Protocol number | “AL102-504” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Completed” |
| Study start (actual) | “2025-02-25” |
| Primary completion (actual) | “2025-03-11” |
| Study completion (actual) | “2025-03-26” |
| Last update posted | “2025-09-26” |
| Site | “Frontage Laboratories, Inc.”; “Secaucus” |

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="heading-3.1.7.3"></a>

##### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

###### Single-center, open-label, single-dose radiolabel study

> “This is a single-center, open-label, Phase 1, mass balance study of varegacestat administered as a single oral dose (containing ~100 µCi) [14C]varegacestat in 6 healthy male participants.”
> “Whole blood, plasma, urine, feces, and vomitus (if any, up to 24 hours post-dose) will be collected over at least 168 hours post-dose.”

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="topic-3.1.7.3-2"></a>

###### Registry design fields

| Study characteristic | Quoted record |
| --- | --- |
| Phase | “Phase 1” |
| Intervention model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Primary purpose | “Other” |

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="heading-3.1.7.4"></a>

##### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

###### Healthy men aged 18 to 55 years

> “Be a male participant between 18 and 55 years of age, inclusive, at Screening.”
> “Medically healthy based on the absence of clinically significant abnormal vital sign measurements, clinical laboratory test results (especially tests for renal and hepatic function), resting 12-lead Electrocardiogram (ECG) evaluation, and physical examination, as determined by the Investigator at Screening and the Check-In visit.”

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="topic-3.1.7.4-2"></a>

###### Exclusion of recent radiation exposure

> “Have participated in a radiolabeled drug study or have been otherwise exposed to significant diagnostic (excluding dental X-rays), therapeutic, or occupational radiation, where exposure is made known to the Investigator, within one year prior to admission to the clinic for this study.”

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="heading-3.1.7.5"></a>

##### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

###### Single dose of carbon-14-labeled varegacestat as two oral capsules after an overnight fast

> “Following completion of Screening and Day -1 assessments and an overnight fast of at least 10 hours, eligible participants will be administered a single dose (containing ~100 µCi) [14C]varegacestat as 2 oral capsules followed by approximately 240 mL room temperature filtered water on the morning of Day 1.”

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="heading-3.1.7.6"></a>

##### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

###### 3.1.7.6.1 Rationale for Using Mass Balance Recovery as the Primary Endpoint

<a id="topic-3.1.7.6.1-1"></a>

###### Primary endpoint: mass balance

> “The mass balance of varegacestat following administration of a single oral dose (containing ~100 µCi) [14C]varegacestat in healthy adult male participants.”

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="topic-3.1.7.6.1-2"></a>

###### Secondary endpoints: total radioactivity, pharmacokinetics, metabolite profile, and safety

> “The total radioactivity in plasma, whole blood, urine, and feces following administration of a single oral dose (containing ~100 µCi) [14C]varegacestat in healthy adult male participants.”
> “Maximum observed concentration (Cmax) of varegacesatat and AL102-MTB (Varegacestat metabolite) in plasma.”
> “Percentage of each metabolite in urine and feces relative to the administered dose or percentage of metabolites in plasma relative to total drug related exposure AUC.”
> “The safety and tolerability of a single oral dose (containing ~100 µCi) [14C]varegacestat in healthy adult male participants by incidences of treatment-emergent adverse events.”

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="heading-3.1.7.7"></a>

##### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

###### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

###### Actual enrollment

| Study characteristic | Quoted record |
| --- | --- |
| Enrollment (actual) | “6” |

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="heading-3.1.7.7.2"></a>

###### 3.1.7.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.7.8"></a>

##### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

###### 3.1.7.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.7.8.2"></a>

###### 3.1.7.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.7.8.3"></a>

###### 3.1.7.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.7.8.4"></a>

###### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.7.8.5"></a>

###### 3.1.7.8.5 Safety Results

No evidence found.

<a id="heading-3.1.7.9"></a>

##### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

###### Summary

- AL102-504 is known only from its registry record. The record lists the study as “Completed”, with primary completion on 2025-03-11, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so the routes of elimination and the metabolite profile of varegacestat are unknown from public sources.
- The study enrolled 6 healthy men aged 18 to 55 years and gave a single dose of approximately 100 µCi of [14C]varegacestat, so it provides no data in women, in patients with desmoid tumors, or at steady state.

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="heading-3.1.8"></a>

#### 3.1.8 VAR-505

<a id="heading-3.1.8.1"></a>

##### 3.1.8.1 Objective

<a id="topic-3.1.8.1-1"></a>

###### Relative bioavailability and bioequivalence of capsule formulations

> “A Phase 1, Open-Label, Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Varegacestat Administered in Different Dose Forms in Healthy Participants”
> “This is an open-label, randomized, crossover study to evaluate the relative bioavailability (rBA) and bioequivalence (BE) of a test capsule formulation of varegacestat compared to reference capsules formulation under fasting conditions.”

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="heading-3.1.8.2"></a>

##### 3.1.8.2 Location and Study Date

<a id="topic-3.1.8.2-1"></a>

###### Registry status, dates, and site

| Study characteristic | Quoted record |
| --- | --- |
| Protocol number | “VAR-505” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Recruiting” |
| Study start (actual) | “2026-05-21” |
| Primary completion (estimated) | “2027-05” |
| Study completion (estimated) | “2027-05” |
| First posted | “2026-05-27” |
| Last update posted | “2026-10-29” |
| Site | “Celerion, Inc.”; “Tempe” |

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="heading-3.1.8.3"></a>

##### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

###### Randomized, open-label, two-part crossover

| Study characteristic | Quoted record |
| --- | --- |
| Phase | “Phase 1” |
| Allocation | “Randomized” |
| Intervention model | “Crossover Assignment” |
| Masking | “None (Open Label)” |
| Primary purpose | “Other” |
| Part 1 sequences | “Part 1: Reference Formulation, then Test Formulation A”; “Part 1: Test Formulation A, then Reference Formulation” |
| Part 2 sequences | “Part 2: Reference Formulation, then Test Formulation B”; “Part 2: Test Formulation B, then Reference Formulation”; “Part 2: Reference Formulation, then Test Formulation C”; “Part 2: Test Formulation C, then Reference Formulation” |

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="heading-3.1.8.4"></a>

##### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

###### Healthy nonsmoking adults aged 18 to 55 years

> “Healthy, adult, female of non childbearing potential or male, 18 to 55 years of age, inclusive, at the screening visit”
> “Continuous non-smoker who has not used nicotine and tobacco containing products for at least 3 months prior to the first dosing”
> “BMI ≥ 18.0 and ≤ 32.0 kg/m2 and with a body weight > 50 kg at the screening visit”
> “Able to swallow multiple capsules”

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="topic-3.1.8.4-2"></a>

###### Exclusion criteria

> “History or presence of hypersensitivity or idiosyncratic reaction to varegacestat or related compounds”
> “Liver disease or dysfunction; Gilbert's syndrome”
> “Renal dysfunction or glomerulonephritis”

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="heading-3.1.8.5"></a>

##### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

###### Oral reference and test formulations

| Intervention | Quoted record |
| --- | --- |
| Reference | “Varegacestat Reference Formulation” |
| Test formulations | “Varegacestat Test Formulation A”; “Varegacestat Test Formulation B”; “Varegacestat Test Formulation C” |
| Route | “Oral administration” |

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="heading-3.1.8.6"></a>

##### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

###### 3.1.8.6.1 Rationale for Using Pharmacokinetic Parameters as the Primary Endpoint

<a id="topic-3.1.8.6.1-1"></a>

###### Primary endpoints: relative bioavailability by AUC and Cmax

> “Evaluate the rBA of varegacestat by AUC0-t”
> “Evaluate the rBA of varegacestat by AUC0-inf”
> “Evaluate the rBA of varegacestat by Cmax”

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="topic-3.1.8.6.1-2"></a>

###### Secondary endpoints: safety and tolerability

> “Assess the safety and tolerability of varegacestat by incidence of treatment emergent adverse events”
> “Assess the safety and tolerability of varegacestat by incidence of changes from baseline of 12-lead ECG assessments”

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="heading-3.1.8.7"></a>

##### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

###### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

###### Estimated enrollment

| Study characteristic | Quoted record |
| --- | --- |
| Enrollment (estimated) | “44” |

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="heading-3.1.8.7.2"></a>

###### 3.1.8.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.8.8"></a>

##### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

###### 3.1.8.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.8.8.2"></a>

###### 3.1.8.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.8.8.3"></a>

###### 3.1.8.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.8.8.4"></a>

###### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.8.8.5"></a>

###### 3.1.8.8.5 Safety Results

No evidence found.

<a id="heading-3.1.8.9"></a>

##### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

###### Summary

- VAR-505 is known only from its registry record. The record lists the study as “Recruiting”, with an actual start on 2026-05-21 and estimated primary completion in 2027-05, and no results are available.
- The registry record names a reference formulation and test formulations A, B, and C without stating their strengths or composition, so the relationship between the test capsules and the capsules used in RINGSIDE or proposed for marketing cannot be determined from the record.
- The study enrolls healthy adults aged 18 to 55 years under fasting conditions, with an estimated enrollment of 44 participants.

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
